<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JOP</journal-id>
<journal-id journal-id-type="hwp">spjop</journal-id>
<journal-id journal-id-type="nlm-ta">J Psychopharmacol</journal-id>
<journal-title>Journal of Psychopharmacology</journal-title>
<issn pub-type="ppub">0269-8811</issn>
<issn pub-type="epub">1461-7285</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0269881113494937</article-id>
<article-id pub-id-type="publisher-id">10.1177_0269881113494937</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Bradley</surname><given-names>Andrew J</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Lenox-Smith</surname><given-names>Alan J</given-names></name>
</contrib>
<aff id="aff1-0269881113494937">Eli Lilly &amp; Co Ltd, Basingstoke, UK</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0269881113494937">Andrew J Bradley, Eli Lilly &amp; Co Ltd, Lilly House, Priestley Road, Basingstoke, RG24 9NL, UK. Email: <email>bradley_andrew_j@lilly.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>27</volume>
<issue>8</issue>
<issue-title>Special issue on Noradrenaline</issue-title>
<fpage>740</fpage>
<lpage>758</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">British Association for Psychopharmacology</copyright-holder>
</permissions>
<abstract>
<p>Selective serotonin reuptake inhibitors (SSRIs) are recommended as first-line pharmacological treatment for depression and are the most commonly prescribed class of antidepressants. However, there is substantial evidence that noradrenaline has a role in the pathogenesis and treatment of depression. This review aims to examine the evidence of including noradrenaline reuptake inhibition with serotonin reuptake inhibition with respect to increasing efficacy in the treatment of depression. Evidence from meta-analysis of randomised controlled trials (RCTs) and randomised pragmatic trials was found in support of greater efficacy of the serotonin noradrenaline reuptake inhibitors (SNRIs), venlafaxine and duloxetine, in moderate to severe depression compared to SSRIs but no evidence was found for superiority of milnacipran. There is sufficient current evidence that demonstrates an increase in efficacy, when noradrenaline reuptake is added to serotonin (5-HT) reuptake, to suggest that patients with severe depression or those who have failed to reach remission with a SSRI may benefit from treatment with a SNRI. However, as these conclusions are drawn from the evidence derived from meta-analyses and pragmatic trials, large adequately powered RCTs using optimal dosing regimens and clinically relevant outcome measures in severe depression and SSRI treatment failures are still required to confirm these findings.</p>
</abstract>
<kwd-group>
<kwd>Selective serotonin reuptake inhibitor</kwd>
<kwd>serotonin noradrenaline reuptake inhibitor</kwd>
<kwd>noradrenaline</kwd>
<kwd>serotonin</kwd>
<kwd>depression</kwd>
<kwd>efficacy</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0269881113494937" sec-type="intro">
<title>Introduction</title>
<p>Ever since the Danish University Antidepressant Group (DUAG) found clomipramine to be more effective than citalopram and paroxetine (<xref ref-type="bibr" rid="bibr19-0269881113494937">DUAG, 1986</xref>, <xref ref-type="bibr" rid="bibr20-0269881113494937">1990</xref>), there has been controversy as to whether dual reuptake inhibition of noradrenaline (NA) and serotonin (5-HT) is more effective in the treatment of depression than selective 5-HT reuptake inhibition. This controversy still remains today primarily due to difficulties in performing randomised controlled trials (RCTs) that fairly and reliably detect what may be relatively modest differences between antidepressants. The answer to this question is important as it is reported that as few as one-third of patients treated with selective 5-HT reuptake inhibitors (SSRIs) obtain full remission of their symptoms (<xref ref-type="bibr" rid="bibr89-0269881113494937">Trivedi et al., 2006</xref>). As efficacy differences between active antidepressants are likely to be relatively modest, the primary difficulty in solving the efficacy controversy has been one of adequate sample size and hence statistical power in individual RCTs to reliably detect between-treatment differences (<xref ref-type="bibr" rid="bibr53-0269881113494937">Lieberman et al., 2005</xref>). This situation has led to the publication of numerous meta-analyses to attempt to clarify this issue. However, rather than improving the clarity of our understanding of the relative efficacy of 5-HT/NA reuptake inhibitors (SNRIs) and SSRIs, these meta-analyses may have inadvertently added to the controversy and confusion. Different conclusions have been drawn probably due to methodological differences and included RCTs making careful consideration of these issues necessary when interpreting results.</p>
<p>In this review, we will attempt to clarify the question of what does NA reuptake inhibition in addition to 5-HT reuptake inhibition bring to the treatment of depression, focusing on efficacy by examining two main bodies of evidence. First, a systematic review of meta-analyses of RCTs comparing the second-generation SNRIs (duloxetine, desvenlafaxine, milnacipran and venlafaxine) to SSRIs in the treatment of depression will be performed. Secondly, we will examine the evidence from large randomised pragmatic trials comparing second-generation SNRIs to SSRIs in the treatment of depression. Large randomised trials are required to test the hypotheses generated from meta-analyses (<xref ref-type="bibr" rid="bibr53-0269881113494937">Lieberman et al., 2005</xref>) and due to their often open-label design and broad inclusion criteria, they are unlikely to be included in meta-analyses of RCTs and therefore provide information additional to that obtained from meta-analyses. We have chosen to restrict our review to second-generation SNRIs as they lack the antagonism of histamine, acetylcholine and α1 adrenergic receptors that the tricyclic antidepressant (TCA) SNRIs possess, making them more similar to the SSRIs but with the addition of NA reuptake inhibition (<xref ref-type="bibr" rid="bibr23-0269881113494937">Deecher et al., 2006</xref>; <xref ref-type="bibr" rid="bibr72-0269881113494937">Puozzo et al., 2002</xref>; <xref ref-type="bibr" rid="bibr74-0269881113494937">Richelson, 2003</xref>). The antagonism of these peripheral receptors can cause sedation and adverse events such as constipation and dry mouth (<xref ref-type="bibr" rid="bibr74-0269881113494937">Richelson, 2003</xref>) that may therefore influence (in both a positive and negative way) scores on the Hamilton Depression Rating Scale (HDRS) through actions other than monoamine reuptake inhibition. Although we will report remission rates, response rates and mean differences in rating scale score, since remission is the primary goal of antidepressant treatment (<xref ref-type="bibr" rid="bibr62-0269881113494937">National Institute for Health and Clinical Excellence, 2010</xref>), we will focus on the remission outcomes.</p>
</sec>
<sec id="section2-0269881113494937" sec-type="methods">
<title>Methods</title>
<sec id="section3-0269881113494937">
<title>Search strategy and inclusion criteria</title>
<sec id="section4-0269881113494937">
<title>Systematic review of meta-analyses</title>
<p>Ovid, Medline, Embase and PsychInfo were searched for meta-analyses comparing second-generation SNRI antidepressants (duloxetine, desvenlafaxine, milnacipran and venlafaxine) to SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine and sertraline) in the treatment of depression. In Embase the search was restricted to major articles and clinical trials for the specific drugs plus the drug therapy of depression. The Medline search was not restricted to major articles, but the subheadings ‘therapeutic use for the drugs’ and ‘drug therapy for depressive disorder’ were used. There were no such restrictions in PsychInfo. We also searched the reference lists of identified meta-analyses and the Cochrane database of systematic reviews for further articles that may not have been identified by our search. Abstracts of identified articles were examined and selected or rejected based on the following inclusion and exclusion criteria.</p>
<list id="list1-0269881113494937" list-type="bullet">
<list-item><p>Meta-analyses of RCTs of head-to-head studies are included if they are comparing the efficacy of SNRIs and SSRIs in the acute treatment (6–12 weeks) of depression that report odds ratios (OR) of response and/or remission rates with 95% confidence intervals (CIs), percentage response and/or remission rates, or standardised mean difference (SMD) in change in rating scale score.</p></list-item>
<list-item><p>Meta-analyses of RCT summary data and patient-level or pooled meta-analyses are included as recommended by the consensus statement for comparing antidepressants (<xref ref-type="bibr" rid="bibr53-0269881113494937">Lieberman et al., 2005</xref>).</p></list-item>
<list-item><p>Network or multiple treatment comparison meta-analyses are excluded as they may be subject to greater bias than direct comparisons (<xref ref-type="bibr" rid="bibr76-0269881113494937">Schacht et al., 2013</xref>) and it has been stated that direct comparisons should take precedence in forming the basis for drawing conclusions (<xref ref-type="bibr" rid="bibr35-0269881113494937">Higgins and Green, 2011</xref>).</p></list-item>
<list-item><p>Meta-analyses in paediatric or exclusively elderly patients are excluded.</p></list-item>
<list-item><p>Older meta-analyses that have since been updated by later analyses are excluded with the most up-to-date and inclusive meta-analysis included.</p></list-item>
</list>
<p>We will in addition, where published, report the number needed to treat (NNT). If the NNT is not reported in the paper where remission or response rates are presented, we will calculate the NNT using the reciprocal of the absolute risk reduction for not achieving remission or response with a SNRI compared to a SSRI (<xref ref-type="bibr" rid="bibr18-0269881113494937">Cook and Sackett, 1995</xref>).</p>
</sec>
<sec id="section5-0269881113494937">
<title>Systematic review of pragmatic studies</title>
<p>For the identification of pragmatic studies, Ovid Medline, Embase and PsychInfo were searched for randomised trials comparing the second-generation SNRIs and specific and generic SSRIs in the treatment of depression. Abstracts of identified articles were examined. For inclusion the studies must have: been randomised; included more than 200 patients in each treatment arm; compared treatments in adults (aged&gt;18 years) diagnosed with depression; reported either response or remission rates; and provided additional data not being included in the meta-analyses that we identified.</p>
</sec>
</sec>
</sec>
<sec id="section6-0269881113494937" sec-type="results">
<title>Results</title>
<sec id="section7-0269881113494937">
<title>Systematic review of meta-analyses</title>
<p>A flow diagram of the results of our searches is shown in <xref ref-type="fig" rid="fig1-0269881113494937">Figure 1</xref>. In total, 49 efficacy-related meta-analyses were identified by our search. Twenty-seven of these were excluded with the reasons detailed in <xref ref-type="table" rid="table1-0269881113494937">Table 1</xref>. Fifteen meta-analyses of RCT summary data were included (<xref ref-type="table" rid="table2-0269881113494937">Table 2</xref>) and seven meta-analyses of individual patient data (<xref ref-type="table" rid="table3-0269881113494937">Table 3</xref>). The quality of the selected meta-analyses was variable with respect to the recommendations of <xref ref-type="bibr" rid="bibr53-0269881113494937">Lieberman et al. (2005)</xref>, and the inability or failure to perform sensitivity analyses regarding the effects of dose of antidepressant on efficacy outcomes was particularly apparent. All but one of the included summary-level meta-analyses used systematic search strategies for published data and the majority also did this for unpublished data. The vast majority also made an assessment for publication bias. All seven patient-level meta-analyses were funded by the drug manufacturers of duloxetine, escitalopram and venlafaxine and, with the exception of <xref ref-type="bibr" rid="bibr40-0269881113494937">Kennedy et al. (2009)</xref>, only included RCTs performed by the relevant manufacturer. A funnel-plot analysis to assess for publication bias was performed with the two patient-level analyses for venlafaxine which included trials not sponsored by the manufacturer (<xref ref-type="bibr" rid="bibr63-0269881113494937">Nemeroff et al., 2008</xref>; <xref ref-type="bibr" rid="bibr77-0269881113494937">Schmitt et al., 2009</xref>).</p>
<fig id="fig1-0269881113494937" position="float">
<label>Figure 1.</label>
<caption>
<p>Flow diagram of searches and included meta-analyses.</p>
<p>MDD: major depressive disorder; RCT: randomised controlled trial; SNRI: serotonin noradrenaline reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor.</p>
</caption>
<graphic xlink:href="10.1177_0269881113494937-fig1.tif"/>
</fig>
<table-wrap id="table1-0269881113494937" position="float">
<label>Table 1.</label>
<caption>
<p>Identified meta-analyses comparing the efficacy of serotonin norepinephrine reuptake inhibitors (SNRIs) and selective serotonin reuptake inhibitors (SSRIs) excluded from the review.</p>
</caption>
<graphic alternate-form-of="table1-0269881113494937" xlink:href="10.1177_0269881113494937-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Meta-analysis</th>
<th align="left">Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td><xref ref-type="bibr" rid="bibr71-0269881113494937">Puech et al. (1997)</xref> MILN vs SSRIs</td>
<td>Only 2 RCTs comparing MILN with SSRI which are included in later analyses</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr26-0269881113494937">Einarson et al. (1998)</xref> VENL vs SSRIs</td>
<td>Not a conventional meta-analysis of head to head studies</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr27-0269881113494937">Einarson et al. (1999)</xref> VENL-XR vs SSRIs</td>
<td>Not a conventional meta-analysis of head to head studies</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr28-0269881113494937">Entsuah et al. (2001)</xref> VENL vs SSRIs</td>
<td>Updated by <xref ref-type="bibr" rid="bibr63-0269881113494937">Nemeroff et al. (2008)</xref></td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr86-0269881113494937">Thase et al. (2001)</xref> VENL vs SSRIs</td>
<td>Updated by <xref ref-type="bibr" rid="bibr63-0269881113494937">Nemeroff et al. (2008)</xref></td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr83-0269881113494937">Stahl et al. (2002)</xref> VENL vs SSRIs</td>
<td>Updated by <xref ref-type="bibr" rid="bibr63-0269881113494937">Nemeroff et al. (2008)</xref></td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr34-0269881113494937">Hansen et al. (2005)</xref> SNRIs vs SSRIs</td>
<td>Updated by <xref ref-type="bibr" rid="bibr30-0269881113494937">Gartlehner et al. (2011)</xref></td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr79-0269881113494937">Shelton et al. (2005)</xref> VENL vs SSRIs</td>
<td>No systematic search and only includes five RCTs of VENL XR</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr25-0269881113494937">Eckert &amp; Lancon (2006)</xref></td>
<td>Indirect comparisons made</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr37-0269881113494937">Kasper et al. (2006)</xref> ESC vs VENL</td>
<td>Examined speed of onset</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr55-0269881113494937">Machado et al. (2006)</xref> SNRIs vs SSRIs</td>
<td>Not a conventional meta-analysis of head to head RCTs</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr5-0269881113494937">Ballesteros et al. (2007)</xref> DLX in 6 RCTs</td>
<td>Only odds ratios vs placebo reported</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr69-0269881113494937">Papakostas et al. (2007)</xref> Dual action vs SSRI</td>
<td>95% confidence intervals not reported</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr29-0269881113494937">Gartlehner et al. (2008a)</xref> SNRIs vs SSRIs</td>
<td>Updated by <xref ref-type="bibr" rid="bibr30-0269881113494937">Gartlehner et al. (2011)</xref></td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr31-0269881113494937">Gartlehner et al. (2008b)</xref> SNRIs vs SSRIs</td>
<td>Updated by <xref ref-type="bibr" rid="bibr30-0269881113494937">Gartlehner et al. (2011)</xref></td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr47-0269881113494937">Lam et al. (2008)</xref> Esc vs DLX</td>
<td>Updated by <xref ref-type="bibr" rid="bibr40-0269881113494937">Kennedy et al. (2009)</xref></td>
</tr>
<tr>
<td>Nakagawa et al. (2008) MILN vs SSRIs</td>
<td>Same as Cochrane review 2009 by same authors</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr68-0269881113494937">Papakostas et al. (2008)</xref> Across or within class switch from SSRI</td>
<td>Meta-analysis of non responders to SSRIs, combined non SNRI dual action drugs with SNRIs</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr91-0269881113494937">Weinman et al. (2008)</xref> VENL vs SSRIs</td>
<td>Updated by Scheuler et al. (2010)</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr13-0269881113494937">Cipriani et al. (2009a)</xref> SNRIs vs SSRIs</td>
<td>Multiple treatment comparison</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr32-0269881113494937">Gartlehner et al. (2009)</xref> SNRIs vs SSRIs</td>
<td>Updated by <xref ref-type="bibr" rid="bibr30-0269881113494937">Gartlehner et al. (2011)</xref></td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr33-0269881113494937">Girardi et al. (2009)</xref> DLX vs SSRIs</td>
<td>VENL is included in the SSRI group</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr46-0269881113494937">Korstein et al. (2009)</xref> ESC vs SNRIs</td>
<td>Omitted one ESC vs DLX RCT which was included in <xref ref-type="bibr" rid="bibr40-0269881113494937">Kennedy et al. 2009</xref></td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr64-0269881113494937">Omori et al. (2009)</xref> FLUVOX vs SNRIs</td>
<td>Same analysis as Cochrane review (<xref ref-type="bibr" rid="bibr65-0269881113494937">Omori et al., 2010</xref>)</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr45-0269881113494937">Koesters et al. (2011)</xref> VENL vs SSRIs</td>
<td>Included RCTs were all performed in China and were reported to be of low quality. It was unclear if some RCTs were double reported.</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr10-0269881113494937">Chen et al. (2012)</xref> DLX vs PAROX</td>
<td>Article in Chinese</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr73-0269881113494937">Ramsberg et al. (2012)</xref> SNRIs vs SSRIs</td>
<td>Multiple treatment comparison</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0269881113494937">
<p>DULX: duloxetine; ESC: escitapralam; FLUVOX: fluvoxamine; MILN: milnicipran; PAROX: paroxetine; RCT: randomised controlled trial; VENL: venlaxafine; XR: extended release.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0269881113494937" position="float">
<label>Table 2.</label>
<caption>
<p>Selected meta-analyses of randomised controlled trial (RCT) summary data.</p>
</caption>
<graphic alternate-form-of="table2-0269881113494937" xlink:href="10.1177_0269881113494937-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Publication</th>
<th align="left" colspan="2">Search strategy<hr/></th>
<th align="left">Assessment for publication bias</th>
<th align="left">Test for statistical heterogeneity</th>
<th align="left" colspan="3">Sensitivity or subgroup analyses performed<hr/></th>
<th align="left">Study outcome measures</th>
</tr>
<tr>
<th/>
<th align="left">Published</th>
<th align="left">Unpublished</th>
<th/>
<th/>
<th align="left">Dose</th>
<th align="left">Placebo control</th>
<th align="left">Baseline severity</th>
<th/>
</tr>
</thead>
<tbody>
<tr>
<td colspan="9"><bold>Individual SSRIs vs SNRIs</bold></td>
</tr>
<tr>
<td><bold><xref ref-type="bibr" rid="bibr12-0269881113494937">Cipriani et al. (2005)</xref></bold>
<break/>(fluoxetine)</td>
<td>Yes</td>
<td>Limited</td>
<td>Yes</td>
<td>Yes – fixed and random effects models utilised</td>
<td>Fluoxetine dose</td>
<td>No</td>
<td>No</td>
<td>OR for response</td>
</tr>
<tr>
<td><bold><xref ref-type="bibr" rid="bibr38-0269881113494937">Katzman et al. (2007)</xref></bold>
<break/>(paroxetine)</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes – random effects model utilised</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Rate difference in response and remission. ES from difference in rating scale score reduction</td>
</tr>
<tr>
<td><bold><xref ref-type="bibr" rid="bibr17-0269881113494937">Cipriani et al. (2009b)</xref></bold>
<break/>(escitalopram)</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes – fixed and random effects models utilised</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>OR for response and remission SMD in rating scale score</td>
</tr>
<tr>
<td><bold><xref ref-type="bibr" rid="bibr15-0269881113494937">Cipriani et al. (2010)</xref></bold>
<break/>(sertraline)</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes – fixed and random effects models utilised</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>OR for response and remission SMD in rating scale score</td>
</tr>
<tr>
<td><bold><xref ref-type="bibr" rid="bibr65-0269881113494937">Omori et al. (2010)</xref></bold>
<break/>(fluvoxamine)</td>
<td>Yes</td>
<td>Yes</td>
<td>Not for individual comparisons due to limited number of RCTs</td>
<td>Yes – fixed and random effects models utilised</td>
<td>Not vs individual SNRIs</td>
<td>No</td>
<td>No</td>
<td>OR for response and remission SMD in rating scale score</td>
</tr>
<tr>
<td><bold><xref ref-type="bibr" rid="bibr16-0269881113494937">Cipriani et al. (2012b)</xref></bold>
<break/>(citalopram)</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes where at least 10 RCTs available</td>
<td>Yes – fixed and random effects models utilised</td>
<td>Citalopram dose</td>
<td>No</td>
<td>No</td>
<td>OR for response and remission SMD in rating scale score</td>
</tr>
<tr>
<td colspan="9"><bold>Venlafaxine vs SSRIs</bold></td>
</tr>
<tr>
<td><bold><xref ref-type="bibr" rid="bibr82-0269881113494937">Smith et al. (2002)</xref></bold></td>
<td>Yes</td>
<td>Yes</td>
<td>Yes – no evidence</td>
<td>Random effects utilised for Venlafaxine vs combined SSRIs and fixed effects vs individual SSRIs</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>OR for response and remission. SMD in rating scale score change.</td>
</tr>
<tr>
<td><bold><xref ref-type="bibr" rid="bibr6-0269881113494937">Bauer et al. (2009)</xref></bold></td>
<td>Yes</td>
<td>Yes</td>
<td>Yes – some evidence of publication bias in remission analysis</td>
<td>Yes – random effects model utilised</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>OR for response and remission NNT</td>
</tr>
<tr>
<td><bold><xref ref-type="bibr" rid="bibr30-0269881113494937">Gartlehner et al. (2011)</xref></bold></td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>OR for response</td>
</tr>
<tr>
<td><bold><xref ref-type="bibr" rid="bibr78-0269881113494937">Schueler et al. (2011)</xref></bold></td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes. Random effects model utilised</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>OR for response and remission</td>
</tr>
<tr>
<td><bold><xref ref-type="bibr" rid="bibr21-0269881113494937">De Silva and Hanwella (2012)</xref></bold></td>
<td>Yes</td>
<td>Yes</td>
<td>Yes - possible publication bias was evident in the analysis of only published trials but not in the analysis of published and unpublished trials.</td>
<td>Yes, none detected but random and fixed effects models utilized.</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>OR for response and remission NNT</td>
</tr>
<tr>
<td colspan="9"><bold>Duloxetine vs SSRIs</bold></td>
</tr>
<tr>
<td><bold><xref ref-type="bibr" rid="bibr30-0269881113494937">Gartlehner et al. (2011)</xref></bold></td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>OR for response</td>
</tr>
<tr>
<td><bold><xref ref-type="bibr" rid="bibr78-0269881113494937">Schueler et al. (2011)</xref></bold></td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes. Random effects model utilised</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>OR for response and remission</td>
</tr>
<tr>
<td><bold><xref ref-type="bibr" rid="bibr14-0269881113494937">Cipriani et al. (2012a)</xref></bold></td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes. Random effects model utilised</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>OR for response and remission SMD in rating scale score</td>
</tr>
<tr>
<td colspan="9"><bold>Milnacipran vs SSRIs</bold></td>
</tr>
<tr>
<td><bold><xref ref-type="bibr" rid="bibr67-0269881113494937">Papakostas and Fava (2007)</xref></bold></td>
<td>Pubmed only</td>
<td>No</td>
<td>Yes</td>
<td>No but random effects model utilized to account for between study variation</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>OR for response</td>
</tr>
<tr>
<td><bold><xref ref-type="bibr" rid="bibr61-0269881113494937">Nakagawa et al. (2009)</xref></bold>
<break/>(milnacipran)</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes – fixed and random effects models utilised</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>OR for response and remission SMD in rating scale score</td>
</tr>
<tr>
<td colspan="9"><bold>Pooled SSRIs vs pooled SNRIs</bold></td>
</tr>
<tr>
<td><bold><xref ref-type="bibr" rid="bibr54-0269881113494937">Machado &amp; Einarson (2010)</xref></bold></td>
<td>Yes</td>
<td>No</td>
<td>Yes – potential bias detected</td>
<td>Yes – none identified. Random effects model utilised.</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>OR for remission</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0269881113494937">
<p>NNT: number needed to treat; OR: odds ratio; RCT: randomised controlled trial; SNRI: serotonin noradrenaline reuptake inhibitor; SMD: standard mean difference; SSRI: selective serotonin reuptake inhibitor; ES: effect size.</p>
</fn>
<fn id="table-fn3-0269881113494937">
<p>Response defined as 50% reduction in rating scale score. Remission defined as HDRS<sub>17</sub>≤7.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table3-0269881113494937" position="float">
<label>Table 3.</label>
<caption>
<p>Characteristics of included meta-analyses using individual patient data from randomised controlled studies of serotonin and noradrenaline reuptake inhibitors (SNRIs) versus selective serotonin reuptake inhibitors (SSRIs) in the acute treatment of depression.</p>
</caption>
<graphic alternate-form-of="table3-0269881113494937" xlink:href="10.1177_0269881113494937-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Publication</th>
<th align="left">Source of patient data</th>
<th align="left">Test for statistical heterogeneity</th>
<th align="left">Sensitivity or subgroup analyses performed</th>
<th align="left">Method of dealing with study selection bias</th>
<th align="left">Study outcome measures</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="6"><bold>Venlafaxine vs SSRIs</bold></td>
</tr>
<tr>
<td><bold><xref ref-type="bibr" rid="bibr63-0269881113494937">Nemeroff et al. (2008)</xref> VENL vs SSRIs</bold></td>
<td>34 RCTs sponsored by the manufacturer of VENL</td>
<td>Yes – none identified but fixed and random effects models utilised</td>
<td>Contribution of individual studies, study type, presence of placebo control</td>
<td>A funnel plot analysis was performed including trials not performed by the manufacturer.</td>
<td>OR for remission NNT</td>
</tr>
<tr>
<td><bold><xref ref-type="bibr" rid="bibr77-0269881113494937">Schmitt et al. (2009)</xref> VENL vs SSRIs by baseline depression severity</bold></td>
<td>31 RCTs using the HDRS<sub>17</sub> sponsored by the manufacturer of VENL</td>
<td>Yes – none identified</td>
<td>Baseline depression severity</td>
<td>A funnel plot analysis was performed including trials not performed by the manufacturer.</td>
<td>OR for remission NNT</td>
</tr>
<tr>
<td colspan="6"><bold>Duloxetine vs SSRIs</bold></td>
</tr>
<tr>
<td><bold><xref ref-type="bibr" rid="bibr88-0269881113494937">Thase et al. (2007)</xref> DLX vs SSRIs</bold></td>
<td>6 RCTs sponsored by the manufacturer of DLX</td>
<td>Yes – none identified</td>
<td>None</td>
<td>None</td>
<td>OR for remission</td>
</tr>
<tr>
<td><bold><xref ref-type="bibr" rid="bibr57-0269881113494937">Mallinckrodt et al. (2007)</xref> DLX vs SSRIs</bold></td>
<td>7 RCTs sponsored by the manufacturer of DLX</td>
<td>None but studies were designed for pooling</td>
<td>Effect of dose of DLX on efficacy compared with SSRIs</td>
<td>None</td>
<td>OR for remission Change in rating scale score</td>
</tr>
<tr>
<td colspan="6"><bold>Escitalopram vs SNRIs</bold></td>
</tr>
<tr>
<td><bold><xref ref-type="bibr" rid="bibr48-0269881113494937">Lam et al. (2010)</xref> ESC vs pooled SNRIs</bold></td>
<td>3 RCTs sponsored by the manufacturer of ESC.</td>
<td>No</td>
<td>None</td>
<td>None</td>
<td>MADRS score at 8 weeks, response and remission rates</td>
</tr>
<tr>
<td><bold><xref ref-type="bibr" rid="bibr40-0269881113494937">Kennedy et al. (2009)</xref> ESC vs pooled SNRIs</bold></td>
<td>4 RCTs sponsored by manufacturers of ESC, 1RCT sponsored by the manufacturer of DLX.</td>
<td>Yes – none identified</td>
<td>Yes – length of clinical trial and inclusion of failed trials</td>
<td>None for analysis of ESC with SNRIs</td>
<td>Mean difference in change in rating scale score</td>
</tr>
<tr>
<td><bold><xref ref-type="bibr" rid="bibr39-0269881113494937">Kennedy et al. (2006)</xref> ESC vs VENL</bold></td>
<td>2 RCTs sponsored by manufacturer of ESC comparing ESC to VENL-XR</td>
<td>Yes – none identified fixed effects model used</td>
<td>Yes, dose, placebo control arm, fixed vs flexible dose, trial length.</td>
<td>None</td>
<td>OR for response and remission. SMD in change in rating scale score.</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0269881113494937">
<p>DLX: duloxetine; ESC : escitalopram; FLUVOX: fluvoxamine; MADRS: Montgomery Asberg Depression Rating Scale; MILN: milnacipran; NNT: needed to treat; OR: odds ratio; PAROX: paroxetine; RCT: randomised controlled trial; SMD: standardised mean difference; VENL: venlafaxine; XR: extended release.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section8-0269881113494937">
<title>Systematic review of randomised pragmatic trials</title>
<p>Three hundred and seventy articles were identified by our search. Four of these trials met our inclusion criteria and were included in our review (<xref ref-type="table" rid="table4-0269881113494937">Table 4</xref>).</p>
<table-wrap id="table4-0269881113494937" position="float">
<label>Table 4.</label>
<caption>
<p>Randomised pragmatic trials comparing serotonin norepinephrine reuptake inhibitors (SNRIs) to selective serotonin reuptake inhibitors (SSRIs) in the treatment of depression.</p>
</caption>
<graphic alternate-form-of="table4-0269881113494937" xlink:href="10.1177_0269881113494937-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Publication and study length</th>
<th align="left">Patient population</th>
<th align="left">Antidepressants and Dosing</th>
<th align="left">Outcomes and NNT* (statistically significant results in bold)</th>
</tr>
</thead>
<tbody>
<tr>
<td><xref ref-type="bibr" rid="bibr4-0269881113494937">Baldomero et al. (2005)</xref><break/>24 weeks<break/>VENL vs SSRIs</td>
<td>Psychiatry speciality outpatients<break/>DSM IV depression (75%); dysthymia (16.3%); minor depression (8.7%).<break/>Mean HDRS<sub>17</sub> approximately 23.5<break/>Patients enrolled demonstrated inadequate response or intolerance to conventional antidepressants (excluding venlafaxine).</td>
<td>Flexible dosing over full dose ranges<break/>VENL n=1632 (164 mg/day)<break/>CIT n=294 (31 mg/day)<break/>FLX n=248 (30 mg/day)<break/>PAR n=312 (29 mg/day)<break/>SERT n=279 (109 mg/day)(Mean dose at endpoint in brackets)</td>
<td><underline>Primary outcomes Remission and Response Rates</underline>
<break/><bold>Remission rates VENL 59.3%; CIT 52%; FLX 52%; PAR 51.6%; SERT 52.7% (all p&lt;0.05)</bold>
<break/><bold>VENL vs CIT OR 1.34 (95% CI 1.04–1.72) NNT = 14</bold>
<break/><bold>VENL vs FLX OR 1.34 (95% CI 1.03–1.75) NNT = 14</bold>
<break/><bold>VENL vs PAR OR 1.36 (95% CI 1.07–1.74) NNT = 13</bold>
<break/><bold>VENL vs SERT OR 1.31 (95% CI 1.01–1.69) NNT = 16</bold>
<break/><bold>Response rate VENL 77.6%; CIT 71.3%; FLX 70.2%; PAR 72.9%; SERT 70.6% (all p&lt;0.05 except vs PAR).</bold>
<break/><bold>VENL vs CIT OR 1.39 (95% CI 1.05–1.84) NNT = 16</bold>
<break/><bold>VENL vs FLX OR 1.47 (95% CI 1.10–2.98) NNT = 14</bold>
<break/><bold>VENL vs PAR OR not stated</bold>
<break/><bold>VENL vs SERT OR 1.44 (95% CI 1.09–1.92) NNT = 15</bold>
<break/><underline>Secondary outcomes change in HDRS<sub>17</sub></underline>
<break/>Results only stated vs all other antidepressants which includes mirtazapine and other non SSRI antidepressants.</td>
</tr>
<tr>
<td rowspan="4"><xref ref-type="bibr" rid="bibr75-0269881113494937">Rush et al. (2006)</xref><break/>14 weeks<break/>VENL vs SERT</td>
<td rowspan="4">Adult outpatients with non psychotic DSM IV depression seeking treatment in primary or secondary care. All patients had failed to reach remission with or were intolerant to up to 14 weeks of flexibly dosed CIT (20–60mg/day).<break/>Mean HDRS baseline score = 18.9+/-7.3</td>
<td>Flexibly dosed</td>
<td><underline>Primary outcome remission on HDRS</underline>17</td>
</tr>
<tr>
<td>VENL 75–375mg/day (193.6mg/day)</td>
<td>VENL 24.8% SERT 17.6% (<italic>p</italic>=n.s.) NNT = 14</td>
</tr>
<tr>
<td>SERT 50–200mg/day (135.3mg/day)</td>
<td><underline>Secondary outcome remission on QIDS-SR-16</underline></td>
</tr>
<tr>
<td>(Mean dose at endpoint in brackets)</td>
<td>VENL 25.0% SERT 26.6% (<italic>p</italic>=n.s.)</td>
</tr>
<tr>
<td rowspan="16"><xref ref-type="bibr" rid="bibr87-0269881113494937">Thase et al. (2011)</xref>180 days(6 months)VENL vs SSRIs</td>
<td rowspan="16">Adult outpatients aged ≥ 18 years and judged by the physician to be experiencing an episode of MDD with stable symptoms for the previous 2 months that required initiation of antidepressant treatment or change from the current treatment regimen. Met diagnostic criteria for MDD according to the Mental Health Screener and scored ≥ 20 on HDRS<sub>17</sub></td>
<td rowspan="16">Patients initiated on VENL-ER 37.5 mg/d (<italic>n</italic>=688) for 4 days, followed by 75 mg/d thereafter; FLX (<italic>n</italic>=114), PAR (<italic>n</italic>=131), or CIT (<italic>n</italic>=259) 20 mg/d; or SERT(<italic>n</italic>=193) 50 mg/day. Dose increases permitted at day 30 (VENL ER 150 mg/d; FLX, PAR, or CIT 40 mg/d; or SERT 100 mg/d) and day 60 (VENL-ER 225 mg/d, FLX 80 mg/d, PAR 50 mg/d, CIT 40 mg/d, or SERT 200 mg/d) on the basis of treatment response.</td>
<td><underline>Primary outcome remission at day 180 on HDRS</underline>17 <underline>&lt;7</underline></td>
</tr>
<tr>
<td>Day 180 VENL-ER 35.5% Pooled SSRI 32% (<italic>p</italic>=0.195)</td>
</tr>
<tr>
<td><underline>Secondary outcomes</underline></td>
</tr>
<tr>
<td>Remission rates at:</td>
</tr>
<tr>
<td><bold>Day 30 VENL-ER 13.1% SSRIs 9.3% (<italic>p</italic>=0.029)</bold></td>
</tr>
<tr>
<td><bold>Day 60 VENL-ER 23.3% SSRIs 18.4% (<italic>p</italic>=0.028)</bold></td>
</tr>
<tr>
<td><bold>Day 90 VENL-ER 29.1% SSRIs 23.7% (<italic>p</italic>=0.025)</bold></td>
</tr>
<tr>
<td><bold>Day 135 VENL-ER 32.7% SSRIs 27.0% (<italic>p</italic>=0.022)</bold></td>
</tr>
<tr>
<td><bold>VENL-ER patients experienced a shorter time to remission (<italic>p</italic>=0.006)</bold></td>
</tr>
<tr>
<td><bold>VENL-ER patients had lower mean ± SD HDRS<sub>17</sub> scores versus SSRI patients (11.7 ± 8.76 vs 13.1 ± 9.26 at study day 180, respectively; <italic>P</italic> = .007)</bold></td>
</tr>
<tr>
<td>VENL-ER MMRM model adjusted mean HDRS<sub>17</sub> change from baseline: −15.33 [95% CI −16.05 to −14.60] vs SSRIs −14.32 [95% CI −15.06 to −13.58], <italic>P</italic> = .0538).</td>
</tr>
<tr>
<td><bold>Difference in MMRM model-adjusted treatment difference for mean change in:</bold></td>
</tr>
<tr>
<td><bold>CGI-S −0.27 [95% CI −0.41 to −0.13]; <italic>p</italic> = .0002);</bold></td>
</tr>
<tr>
<td><bold>HADS-A total −0.38 [95% CI −0.73to −0.04]; <italic>p</italic> = .03);</bold></td>
</tr>
<tr>
<td><bold>HDRS6 −0.83 [95% CI −1.45to −0.21]; <italic>p</italic> = .009);</bold></td>
</tr>
<tr>
<td><bold>QIDS-SR16 (−1.01 [−1.56, −0.47]; <italic>p</italic>= .0003)</bold></td>
</tr>
<tr>
<td rowspan="20"><xref ref-type="bibr" rid="bibr58-0269881113494937">Martinez et al., (2012)</xref><break/>12 weeks<break/>DLX vs SSRIs</td>
<td rowspan="20">Adult outpatients with non psychotic DSM IV with PHQ-9 score ≥ 16 and QIDS-SR-16 ≥ 20. Patients taking SSRIs or VENL were allowed to participate if they had not adequately responded to treatment.</td>
<td rowspan="20">Flexibly dosed over full dose ranges<break/>DLX n=372 (70.8mg/day)<break/>CIT n=157 (33.1mg/day)<break/>FLX n=57 (42.3mg/day)<break/>PAR n=45 (29mg/day)<break/>SERT n=119 (109mg/day)(Mean dose at endpoint in brackets)</td>
<td><underline>Primary outcome remission on QIDS-SR-16 DLX vs pooled SSRIs</underline></td>
</tr>
<tr>
<td>Remission rate DLX 36% SSRIs 32% (<italic>p</italic>=0.260) NNT = 25*</td>
</tr>
<tr>
<td><underline>A priori subgroup analysis of primary outcome</underline></td>
</tr>
<tr>
<td>Remission rate baseline QIDS-SR &lt;21 DLX 35% SSRI 34% (<italic>p</italic>=0.809)</td>
</tr>
<tr>
<td>Remission rate baseline QIDS-SR &gt;22 DLX 38% SSRI 29% (<italic>p</italic>=0.156) NNT = 12</td>
</tr>
<tr>
<td><underline>Secondary outcome response on QIDS-SR and response and remission on HDRS<sub>17</sub></underline></td>
</tr>
<tr>
<td>Response QIDS-SR DLX 71% SSRI 64% (p =0.085) NNT = 15</td>
</tr>
<tr>
<td><bold>Remission HDRS<sub>17</sub> DLX 53% SSRI 44% (<italic>p</italic>=0.034) NNT = 12</bold></td>
</tr>
<tr>
<td><bold>Response HDRS<sub>17</sub> DLX 73% SSRI 61% (<italic>p</italic>=0.001) NNT = 9</bold></td>
</tr>
<tr>
<td><underline>A priori subgroup analysis of secondary measures</underline></td>
</tr>
<tr>
<td>Remission on HDRS<sub>17</sub> in patients with QIDS-SR 20-21</td>
</tr>
<tr>
<td>DLX 49% SSRI 47% (<italic>p</italic>=0.696)</td>
</tr>
<tr>
<td><bold>Remission on HDRS<sub>17</sub> in patients with QIDS-SR ≥21</bold></td>
</tr>
<tr>
<td><bold>DLX 58% SSRI 42% (<italic>p</italic>=0.009) NNT = 7</bold></td>
</tr>
<tr>
<td>Remission on HDRS<sub>17</sub> in patients with HDRS<sub>17</sub> &lt;25</td>
</tr>
<tr>
<td>DLX 47% SSRI 39% (<italic>p</italic>=0.213) NNT = 13</td>
</tr>
<tr>
<td>Remission on HDRS<sub>17</sub> in patients with HDRS<sub>17</sub> ≥25</td>
</tr>
<tr>
<td>DLX 58% SSRI 48% (<italic>p</italic>=0.083) NNT = 10</td>
</tr>
<tr>
<td>Mean change in QIDS-SR DLX – 13.4 SSRI -12.6 (<italic>p</italic>=0.07)</td>
</tr>
<tr>
<td><bold>Mean change in HDRS<sub>17</sub> DLZ – 17 SSRI -15.3 (p&lt;0.01)</bold></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0269881113494937">
<p>CGI-S: Clinical Global Impression Scale; CI: confidence interval; CIT: citalopram; ER: extended release; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders Fourth Edition; FLX: fluoxetine; HADS: Hospital Anxiety and Depression Scale; HDRS<sub>17</sub>: Hamilton Depression Rating Scale 17 item; MDD: major depressive disorder; MMRM: mixed effects model for repeated measures; NNT: number needed to treat; n.s.: non statistically significant; PAR: paroxetine; PHQ-9: personal health questionnaire 9 item; QIDS-SR-16: 16 item quick inventory of depressive symptomatology- self rated; SD: standard deviation; SERT: sertraline; SSRI: selective serotonin reuptake inhibitor; VENL: venlafaxine.</p>
</fn>
<fn id="table-fn6-0269881113494937">
<p>Remission defined as HDRS<sub>17</sub>≤7 or QIDS-SR-16≤5. <sup>a</sup>All NNTs were calculated using the reciprocal of the absolute difference in response or remission rates.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section9-0269881113494937">
<title>Venlafaxine versus SSRIs</title>
<sec id="section10-0269881113494937">
<title>Meta-analyses</title>
<p>Venlafaxine was compared to SSRIs in 10 of the RCT summary-level meta-analyses and three of the patient-level meta-analyses (<xref ref-type="table" rid="table5-0269881113494937">Table 5</xref>). The largest analysis of RCT summary data included 38 RCTs in the response analysis and 31 in the remission analysis (<xref ref-type="bibr" rid="bibr21-0269881113494937">De Silva and Hanwella, 2012</xref>). The largest patient-level meta-analysis included 7812 patients from 34 RCTs in a remission analysis (<xref ref-type="bibr" rid="bibr63-0269881113494937">Nemeroff et al., 2008</xref>). Mean daily doses at the eight-week endpoint reported by <xref ref-type="bibr" rid="bibr63-0269881113494937">Nemeroff et al. (2008)</xref> were venlafaxine 151 mg, citalopram 38 mg, fluoxetine 37 mg, fluvoxamine 175 mg, paroxetine 25 mg and sertraline 127 mg. Dose of venlafaxine was restricted to 150 mg/day in 17/34 of the RCTs, and 6/34 RCTs restricted the dose of SSRI to the lowest minimum dose. A placebo control was present in 9/34 of the RCTs and the severity of depression was generally moderate to severe (mean baseline HDRS<sub>21</sub> range 20–29).</p>
<table-wrap id="table5-0269881113494937" position="float">
<label>Table 5.</label>
<caption>
<p>Efficacy outcomes from meta–analyses comparing venlafaxine to selective serotonin reuptake inhibitors (SSRIs).</p>
</caption>
<graphic alternate-form-of="table5-0269881113494937" xlink:href="10.1177_0269881113494937-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Outcome</th>
<th align="left">Publication</th>
<th align="left">RCTs or patients</th>
<th align="left">Outcome (significant outcomes in bold)</th>
<th align="left">NNT</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="5"><bold>Venlafaxine vs pooled SSRIs</bold></td>
</tr>
<tr>
<td rowspan="10"><bold>Remission</bold></td>
<td><xref ref-type="bibr" rid="bibr63-0269881113494937">Nemeroff et al. (2008)</xref></td>
<td>7812 patients</td>
<td><bold>VENL 5.9% remission advantage vs SSRIs (95% CI 0.038–0.081)</bold></td>
<td>17 (95% CI 12–26)</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr77-0269881113494937">Schmitt et al. (2009)</xref></td>
<td>3928 patients</td>
<td><bold>Baseline HDRS<sub>17</sub>&lt;25 OR 1.35 (95% CI 1.19–1.54)</bold></td>
<td>14</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr77-0269881113494937">Schmitt et al. (2009)</xref></td>
<td>2564 patients</td>
<td><bold>Baseline HDRS<sub>17</sub> ≥25 OR 1.31 (95% CI 1.10–1.54)</bold></td>
<td>17</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr77-0269881113494937">Schmitt et al. (2009)</xref></td>
<td>5836 patients</td>
<td><bold>Baseline HDRS<sub>17</sub>&lt;30 OR 1.31 (95% CI 1.18–1.46)</bold></td>
<td>16</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr77-0269881113494937">Schmitt et al. (2009)</xref></td>
<td>656 patients</td>
<td><bold>Baseline HDRS<sub>17</sub> ≥30 OR 1.55 (95% CI 1.10–2.18)</bold></td>
<td>11</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr21-0269881113494937">De Silva and Hanwella (2012)</xref></td>
<td>31 RCTs<sup><xref ref-type="table-fn" rid="table-fn8-0269881113494937">a</xref></sup></td>
<td><bold>OR 1.14 (95% CI 1.02–1.27)</bold></td>
<td>–</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr21-0269881113494937">De Silva and Hanwella (2012)</xref></td>
<td>24 RCTs<sup><xref ref-type="table-fn" rid="table-fn8-0269881113494937">b</xref></sup></td>
<td><bold>OR 1.13 (95% CI 1.0–1.28)</bold></td>
<td>28</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr6-0269881113494937">Bauer et al. (2009)</xref></td>
<td>23 RCTs</td>
<td><bold>OR 1.19 (95% CI 1.06–1.34)</bold></td>
<td>19 (95% CI 12–57)</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr78-0269881113494937">Schueler et al. (2011)</xref></td>
<td>18 RCTs</td>
<td><bold>OR 1.12 (95% CI 0.98–1.28)</bold></td>
<td><sup>–</sup></td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr82-0269881113494937">Smith et al. (2002)</xref></td>
<td>16 RCTs</td>
<td><bold>OR 1.43 (95% CI 1.21–1.71)</bold></td>
<td><sup>–</sup></td>
</tr>
<tr>
<td><bold>Response</bold></td>
<td><xref ref-type="bibr" rid="bibr21-0269881113494937">De Silva and Hanwella (2012)</xref></td>
<td>38 RCTs<sup><xref ref-type="table-fn" rid="table-fn8-0269881113494937">a</xref></sup></td>
<td><bold>OR 1.17 (95% CI 1.05–1.31)</bold></td>
<td>18</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr6-0269881113494937">Bauer et al. (2009)</xref></td>
<td>29 RCTs</td>
<td><bold>OR 1.15 (95% CI 1.02–1.29)</bold></td>
<td>36 (95% CI 19–763)</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr78-0269881113494937">Schueler et al. (2011)</xref></td>
<td>25 RCTs</td>
<td><bold>OR 1.20 (95% CI 1.07–1.35)</bold></td>
<td><sup>–</sup></td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr21-0269881113494937">De Silva and Hanwella (2012)</xref></td>
<td>25 RCTs<sup><xref ref-type="table-fn" rid="table-fn8-0269881113494937">b</xref></sup></td>
<td><bold>OR 1.17 (95% CI 1.03–1.34)</bold></td>
<td>18</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr82-0269881113494937">Smith et al. (2002)</xref></td>
<td>17 RCTs</td>
<td><bold>OR 1.26 (95% CI 1.02–1.58)</bold></td>
<td>–</td>
</tr>
<tr>
<td><bold>SMD</bold></td>
<td><xref ref-type="bibr" rid="bibr82-0269881113494937">Smith et al. (2002)</xref></td>
<td>19 RCTs</td>
<td><bold>–0.17 (95% CI −0.27 to −0.08)</bold></td>
<td>–</td>
</tr>
<tr>
<td colspan="5"><bold>Venlafaxine vs fluoxetine</bold></td>
</tr>
<tr>
<td><bold>Remission</bold></td>
<td><xref ref-type="bibr" rid="bibr63-0269881113494937">Nemeroff et al. (2008)</xref></td>
<td>4401 patients</td>
<td><bold>VENL 6.6% remission advantage vs FLX (95% CI 0.030–0.095)</bold></td>
<td>16</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr21-0269881113494937">De Silva and Hanwella (2012)</xref></td>
<td>&gt;14 RCTs<sup><xref ref-type="table-fn" rid="table-fn8-0269881113494937">a</xref></sup></td>
<td><bold>OR 1.17 (95% CI 1.01–1.36)</bold></td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr21-0269881113494937">De Silva and Hanwella (2012)</xref></td>
<td>14 RCTs<sup><xref ref-type="table-fn" rid="table-fn8-0269881113494937">b</xref></sup></td>
<td>OR 1.16 (95% CI 0.99–1.34)</td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr6-0269881113494937">Bauer et al. (2009)</xref></td>
<td>11 RCTs</td>
<td><bold>OR 1.18 (95% CI 1.00–1.39)</bold></td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr82-0269881113494937">Smith et al. (2002)</xref></td>
<td>10 RCTs</td>
<td><bold>OR 1.42 (95% CI 1.17–1.73)</bold></td>
<td>–</td>
</tr>
<tr>
<td><bold>Response</bold></td>
<td><xref ref-type="bibr" rid="bibr6-0269881113494937">Bauer et al. (2009)</xref></td>
<td>15 RCTs</td>
<td><bold>OR 1.16 (95% CI 1.01–1.33)</bold></td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr21-0269881113494937">De Silva and Hanwella (2012)</xref></td>
<td>&gt;14 RCTs<sup><xref ref-type="table-fn" rid="table-fn8-0269881113494937">a</xref></sup></td>
<td><bold>OR 1.23 (95% CI 1.05–1.45)</bold></td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr21-0269881113494937">De Silva and Hanwella (2012)</xref></td>
<td>14 RCTs<sup><xref ref-type="table-fn" rid="table-fn8-0269881113494937">b</xref></sup></td>
<td><bold>OR 1.28 (95% CI 1.05–1.55)</bold></td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr82-0269881113494937">Smith et al. (2002)</xref></td>
<td>12 RCTs</td>
<td>OR 1.17 (95% CI 0.99–1.38)</td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr12-0269881113494937">Cipriani et al. (2005)</xref></td>
<td>9 RCTs</td>
<td><bold>OR 1.40 (95% CI 1.15–1.70) (failure to respond FLX vs VENL)</bold></td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr30-0269881113494937">Gartlehner et al.(2011)</xref></td>
<td>5 RCTs</td>
<td><bold>OR 1.47 (95% CI 1.16–1.86)</bold></td>
<td>–</td>
</tr>
<tr>
<td><bold>SMD</bold></td>
<td><xref ref-type="bibr" rid="bibr82-0269881113494937">Smith et al. (2002)</xref></td>
<td>13 RCTs</td>
<td><bold>–0.14 (95% CI −0.22 to −0.06)</bold></td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr12-0269881113494937">Cipriani et al. (2005)</xref></td>
<td>10 RCTs</td>
<td><bold>0.11 (0.00–0.23) (FLX vs VENL)</bold></td>
<td>–</td>
</tr>
<tr>
<td colspan="5"><bold>Venlafaxine vs paroxetine</bold></td>
</tr>
<tr>
<td><bold>Remission</bold></td>
<td><xref ref-type="bibr" rid="bibr63-0269881113494937">Nemeroff et al. (2008)</xref></td>
<td>1464 patients</td>
<td>VENL 4.6% remission advantage vs PAR (95% CI −0.04 to 0.097)</td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr6-0269881113494937">Bauer et al. (2009)</xref></td>
<td>6 RCTs</td>
<td><bold>1.49 (95% CI 1.14–1.96)</bold></td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr21-0269881113494937">De Silva and Hanwella (2012)</xref></td>
<td>&gt;4 RCTs<sup><xref ref-type="table-fn" rid="table-fn8-0269881113494937">a</xref></sup></td>
<td>OR not reported but N.S.</td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr21-0269881113494937">De Silva and Hanwella (2012)</xref></td>
<td>4 RCTs<sup><xref ref-type="table-fn" rid="table-fn8-0269881113494937">b</xref></sup></td>
<td>OR 1.23 (95% CI 0.80–1.87)</td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr82-0269881113494937">Smith et al. (2002)</xref></td>
<td>4 RCTs</td>
<td><bold>OR 1.4 (95% CI 1.05–1.88)</bold></td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr38-0269881113494937">Katzman et al. (2007)</xref></td>
<td>3 RCTs</td>
<td>Rate difference −12.1% (95% CI −28.8 to 4.6) (PAR vs VENL)</td>
<td>–</td>
</tr>
<tr>
<td><bold>Response</bold></td>
<td><xref ref-type="bibr" rid="bibr6-0269881113494937">Bauer et al. (2009)</xref></td>
<td>7 RCTs</td>
<td><bold>OR 1.38 (95% CI 1.05–1.82)</bold></td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr21-0269881113494937">De Silva and Hanwella (2012)</xref></td>
<td>4 RCTs<sup><xref ref-type="table-fn" rid="table-fn8-0269881113494937">b</xref></sup></td>
<td>OR 1.20 (95% CI 0.86–1.68)</td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr21-0269881113494937">De Silva and Hanwella (2012)</xref></td>
<td>&gt;4 RCTs<sup><xref ref-type="table-fn" rid="table-fn8-0269881113494937">a</xref></sup></td>
<td><bold>OR 1.34 (95% CI 1.0–1.8)</bold></td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr82-0269881113494937">Smith et al. (2002)</xref></td>
<td>3 RCTs</td>
<td>OR 1.14 (95% CI 0.78–1.67)</td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr38-0269881113494937">Katzman et al. (2007)</xref></td>
<td>2 RCTs</td>
<td><bold>Rate difference −21.0% (95% CI −34.0 to 8.0) (PAR vs VENL)</bold></td>
<td>–</td>
</tr>
<tr>
<td><bold>SMD</bold></td>
<td><xref ref-type="bibr" rid="bibr82-0269881113494937">Smith et al. (2002)</xref></td>
<td>4 RCTs</td>
<td><bold>–0.19 (95% CI −0.34 to −0.05)</bold></td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr38-0269881113494937">Katzman et al. (2007)</xref></td>
<td>3 RCTs</td>
<td>–0.07 (95 % CI −0.24 to 1.0)</td>
<td>–</td>
</tr>
<tr>
<td colspan="5"><bold>Venlafaxine vs fluvoxamine</bold></td>
</tr>
<tr>
<td><bold>Remission</bold></td>
<td><xref ref-type="bibr" rid="bibr65-0269881113494937">Omori et al. (2010)</xref></td>
<td>2 RCTs</td>
<td>OR 0.54 (95% CI 0.23–1.24) (FLUVOX vs VENL)</td>
<td>–</td>
</tr>
<tr>
<td><bold>Response</bold></td>
<td><xref ref-type="bibr" rid="bibr65-0269881113494937">Omori et al. (2010)</xref></td>
<td>2 RCTs</td>
<td><bold>0.40 (95% CI 0.18–0.92) (FLUVOX vs VENL)</bold></td>
<td>–</td>
</tr>
<tr>
<td colspan="5"><bold>Venlafaxine vs sertraline</bold></td>
</tr>
<tr>
<td><bold>Remission</bold></td>
<td><xref ref-type="bibr" rid="bibr63-0269881113494937">Nemeroff et al. (2008)</xref></td>
<td>1297 patients</td>
<td>VENL 3.4% remission advantage vs SERT (95% CI −0.017 to 0.086)</td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr15-0269881113494937">Cipriani et al. (2010)</xref></td>
<td>3 RCTs</td>
<td>1.00 (95% CI 0.63–1.60) (failure to remission SERT vs VENL)</td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr21-0269881113494937">De Silva and Hanwella (2012)</xref></td>
<td>3 RCTs</td>
<td>OR 1.28 (95% CI 0.71–2.31)</td>
<td>–</td>
</tr>
<tr>
<td><bold>Response</bold></td>
<td><xref ref-type="bibr" rid="bibr15-0269881113494937">Cipriani et al. (2010)</xref></td>
<td>5 RCTs</td>
<td>OR 1.07 (95% CI 0.74–1.54) (failure to respond SERT vs VENL)</td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr21-0269881113494937">De Silva and Hanwella (2012)</xref></td>
<td>3 RCTs</td>
<td>OR 1.21 (95% CI 0.83–1.77)</td>
<td/>
</tr>
<tr>
<td><bold>SMD</bold></td>
<td><xref ref-type="bibr" rid="bibr15-0269881113494937">Cipriani et al. (2010)</xref></td>
<td>4 RCTs</td>
<td>–0.09 (95% CI −0.42 to 0.24) (SERT vs VENL)</td>
<td>–</td>
</tr>
<tr>
<td colspan="5"><bold>Venlafaxine vs escitalopram</bold></td>
</tr>
<tr>
<td><bold>Remission</bold></td>
<td><xref ref-type="bibr" rid="bibr17-0269881113494937">Cipriani et al. (2009b)</xref></td>
<td>2 RCTs</td>
<td>0.91 (95% CI 0.63–1.33) (failure to remission ESC vs VENL)</td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr21-0269881113494937">De Silva and Hanwella (2012)</xref></td>
<td>2 RCTs</td>
<td>OR 0.92 (95% CI 0.62–1.35)</td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr39-0269881113494937">Kennedy et al. (2006)</xref></td>
<td>483 patients</td>
<td>OR 1.29 (95% CI 0.84–1.98) (ESC vs VENL)</td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr39-0269881113494937">Kennedy et al. (2006)</xref></td>
<td>N/A</td>
<td>OR 1.72 (95% CI 0.91–3.25) (ESC vs VENL severe patients) <sup><xref ref-type="table-fn" rid="table-fn8-0269881113494937">c</xref></sup></td>
<td>–</td>
</tr>
<tr>
<td><bold>Response</bold></td>
<td><xref ref-type="bibr" rid="bibr17-0269881113494937">Cipriani et al. (2009b)</xref></td>
<td>2 RCTs</td>
<td>OR 0.86 (95% CI 0.53–1.39) (failure to respond)</td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr21-0269881113494937">De Silva and Hanwella (2012)</xref></td>
<td>2 RCTs</td>
<td>OR 0.86 (95% CI 0.49–1.49)</td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr39-0269881113494937">Kennedy et al. (2006)</xref></td>
<td>483 patients</td>
<td>OR 1.23 (95% CI 0.80–1.89) (ESC vs VENL)</td>
<td/>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr39-0269881113494937">Kennedy et al. (2006)</xref></td>
<td>N/A</td>
<td>OR 1.61 (95% CI 0.85–3.04) (ESC vs VENL severe patients)<sup><xref ref-type="table-fn" rid="table-fn8-0269881113494937">c</xref></sup></td>
<td/>
</tr>
<tr>
<td><bold>SMD</bold></td>
<td><xref ref-type="bibr" rid="bibr17-0269881113494937">Cipriani et al. (2009b)</xref></td>
<td>2 RCTs</td>
<td>–0.07 (95% CI −0.38 to 0.25)</td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr39-0269881113494937">Kennedy et al. (2006)</xref></td>
<td>483 patients</td>
<td>0.38 (95% CI −1.18 to 1.94) (ESC vs VENL)</td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr39-0269881113494937">Kennedy et al. (2006)</xref></td>
<td>N/A</td>
<td>1.57 (95% CI −0.90 to 4.05) (severe patients) <sup><xref ref-type="table-fn" rid="table-fn8-0269881113494937">c</xref></sup></td>
<td>–</td>
</tr>
<tr>
<td colspan="5"><bold>Venlafaxine vs citalopram</bold></td>
</tr>
<tr>
<td><bold>Remission</bold></td>
<td><xref ref-type="bibr" rid="bibr63-0269881113494937">Nemeroff et al. (2008)</xref></td>
<td>539 patients</td>
<td>3.9% remission advantage vs CIT (95% CI −0.041 to 0.119)</td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr21-0269881113494937">De Silva and Hanwella (2012)</xref></td>
<td>2 RCTs</td>
<td>OR 1.01 (95% CI 0.71–1.44)</td>
<td>–</td>
</tr>
<tr>
<td><bold>Response</bold></td>
<td><xref ref-type="bibr" rid="bibr21-0269881113494937">De Silva and Hanwella (2012)</xref></td>
<td>2 RCTs</td>
<td>OR 0.96 (95% CI 0.67–1.37)</td>
<td>–</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-0269881113494937">
<p>CI: confidence interval; CIT: citalopram; DLX: duloxetine; ESC: escitalopram; FLUVOX: fluvoxamine; FLX: fluoxetine; HDRS: Hamilton Depression Rating Scale; MADRS: Montgomery Asberg Depression Rating Scale; N.S.: no significant difference; OR: odds ratio; PAR: paroxetine; RCT: randomised controlled trial; SERT: sertraline; SMD: standard mean difference; VENL: venlafaxine.</p>
</fn>
<fn id="table-fn8-0269881113494937">
<label>a</label>
<p>Includes published and unpublished RCTs, <sup>b</sup>includes only published RCTs, <sup>c</sup>severe patients=MADRS≥30.</p>
</fn>
<fn id="table-fn9-0269881113494937">
<p>Data from Cochrane reviews reported from 6–12 weeks.</p>
</fn>
<fn id="table-fn10-0269881113494937">
<p>Response defined as a reduction of ≥50% from baseline score on the HDRS or MADRS, and remission as achieving an HDRS<sub>17</sub> score ≤7 or a MADRS score ≤10 or 12.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section11-0269881113494937">
<title>Venlafaxine compared to pooled SSRIs</title>
<p>Venlafaxine was consistently found to be superior in remission rates compared to pooled SSRIs with OR for remission ranging from 1.12–1.43. Only the remission analysis reported by <xref ref-type="bibr" rid="bibr78-0269881113494937">Schueler et al. (2011)</xref> failed to find a statistically significant advantage in remission rates for venlafaxine, although this bordered on statistical significance, OR 1.12 (95% CI 0.98–1.28). <xref ref-type="bibr" rid="bibr63-0269881113494937">Nemeroff et al., (2008)</xref> found a remission advantage of 5.9% (<italic>p</italic>&lt;0.001) over SSRIs in their patient-level analysis. NNT for remission ranged from 17–28. <xref ref-type="bibr" rid="bibr77-0269881113494937">Schmitt et al. (2009)</xref> examined remission rates by baseline severity of depression. Venlafaxine was found to be statistically significantly superior in remission rates to pooled SSRIs across all depression levels examined with the greatest OR of 1.55 (95% CI 1.10–2.18) being in those with the highest severity of baseline symptoms (HDRS<sub>17</sub>≥30). This also resulted in the lowest NNT of 11.</p>
</sec>
<sec id="section12-0269881113494937">
<title>Venlafaxine compared to individual SSRIs</title>
<p>Fluoxetine was the most common comparator SSRI with 4401 patients and over 14 RCTs included in the remission analyses. The patient-level meta-analysis found a 6.6% remission advantage for venlafaxine resulting in a NNT of 16 (<xref ref-type="bibr" rid="bibr63-0269881113494937">Nemeroff et al., 2008</xref>) and ORs for remission ranged from 1.16–1.42. Only the effect found in the analysis of published trials (14 RCTs) was not statistically significant but that was borderline (OR 1.16; 95% CI 0.99–1.34). Paroxetine was the next most studied comparator SSRI with 1464 patients and up to six RCTs included in the remission analysis.</p>
<p>The patient-level analysis found a 4.6% remission advantage for venlafaxine that bordered on statistical significance (95% CI −0.04–0.097) and ORs for remission ranged from 1.23–1.49 but not all were statistically significant. Remission rates compared to sertraline were generally in favour of venlafaxine but not statistically significantly so. Fewer patients (1297) and RCTs (3) were available for these analyses. No significant difference was found in remission rates between venlafaxine and fluvoxamine from the meta-analysis of two RCTs (<xref ref-type="bibr" rid="bibr65-0269881113494937">Omori et al., 2010</xref>). ORs for remission favoured escitalopram over venlafaxine (two RCTs or 483 patients) and venlafaxine over citalopram (two RCTs or 539 patients), but neither difference was statistically significant.</p>
</sec>
<sec id="section13-0269881113494937">
<title>Pragmatic randomised trials (<xref ref-type="table" rid="table4-0269881113494937">Table 4</xref>)</title>
<sec id="section14-0269881113494937">
<title>Venlafaxine-extended release (ER) vs SSRIs in primary care patients with depression</title>
<p>This study (<xref ref-type="bibr" rid="bibr87-0269881113494937">Thase et al., 2011</xref>), funded by Pfizer, recruited depressed outpatients from primary care who met diagnostic criteria for major depressive disorder (MDD) according to the mental health screener (<xref ref-type="bibr" rid="bibr44-0269881113494937">Kobak et al., 1997</xref>). Patients who scored ≥20 on the HDRS<sub>17</sub> were randomised to open-label treatment with venlafaxine-ER (<italic>n</italic>=688) or physicians choice of SSRI (citalopram, fluoxetine, paroxetine or sertraline) (<italic>n</italic>=697) for up to 180 days. Treatments were initiated at minimum effective doses but were able to be prescribed flexibly up to their maximum doses after 60 days at clinician discretion. The primary outcome was remission (HDRS<sub>17</sub>≤7) at day 180 and various secondary measures were planned (<xref ref-type="table" rid="table4-0269881113494937">Table 4</xref>). The study was powered to make comparisons between venlafaxine-ER and pooled SSRIs. Remission rates were in favour of venlafaxine at all time points but were not statistically significantly different at the primary endpoint of day 180 although they were at all other time points. Generally secondary efficacy measures were statistically significantly in favour of venlafaxine (<xref ref-type="table" rid="table4-0269881113494937">Table 4</xref>).</p>
</sec>
</sec>
<sec id="section15-0269881113494937">
<title>STAR*D</title>
<p>STAR*D (Sequenced Treatment Alternatives to Relieve Depression) is a large US National Institute for Mental Health-funded study designed to measure remission rates achieved after different sequenced treatment (<xref ref-type="bibr" rid="bibr89-0269881113494937">Trivedi et al., 2006</xref>). Patients seeking treatment with a HDRS<sub>17</sub>≥14 (<italic>n</italic>=2786) were treated with a flexible dose of the SSRI citalopram for up to 14 weeks. Following treatment, 28% of patients met the primary outcome of remission (HDRS<sub>17</sub>≤7) (<xref ref-type="bibr" rid="bibr89-0269881113494937">Trivedi et al., 2006</xref>). Patients who failed to achieve remission (in this case defined as a score of ≥5 on the 16-item Quick Inventory of Depressive Symptomatology-Clinician Rated (QIDS-C-16) or were intolerant of citalopram were eligible to continue to step 2 of the study, where they could choose from several treatment pathways including a switch of antidepressant (<xref ref-type="bibr" rid="bibr75-0269881113494937">Rush et al., 2006</xref>). In this part of the study, 727 patients were randomised to open-label monotherapy with flexible doses of bupropion-sustained release (SR) (<italic>n</italic>=239), sertraline (<italic>n</italic>=238), or venlafaxine-extended release (XR) (<italic>n</italic>=250) for up to 14 weeks. The primary outcome was remission (HDRS<sub>17</sub>≤7). When SSRIs and SNRIs were compared, the remission rates were 17.6% for sertraline and 24.8% for venlafaxine XR. This difference was not statistically significantly different (<italic>p</italic>=0.16), but results of a NNT of 14 for remission with venlafaxine XR over sertraline.</p>
</sec>
<sec id="section16-0269881113494937">
<title>ARGOS</title>
<p>The ARGOS study was an open-label, randomised, multicentre study funded by Wyeth and performed in Spain (<xref ref-type="bibr" rid="bibr4-0269881113494937">Baldomero et al., 2005</xref>). The study compared the efficacy of venlafaxine XR and ‘conventional antidepressants’ (CAs; SSRIs, mirtazapine and other antidepressants) in CA non-responders. Patients with MDD (<italic>Diagnostic and Statistical Manual, Fourth Edition</italic> (DSM-IV)), dysthymia, or minor depression who were referred to an outpatient psychiatric clinic after inadequate response or intolerance to at least four weeks of CA therapy at an adequate dose (63.3% SSRIs) and with a HDRS<sub>17</sub> score≥17 were eligible. Patients (75% with DSM-IV MDD) were randomised to venlafaxine XR (<italic>n</italic>=1632) or a CA other than their initial agent, chosen at the discretion of the treating clinician, (<italic>n</italic>=1465) for 24 weeks of treatment. Baseline mean HDRS<sub>17</sub> was 23.9 in the venlafaxine group and 23.0 in the CA group. Antidepressants were flexibly dosed according to usual clinical practice and investigators’ judgment. The primary endpoint of the study was remission (HDRS<sub>17</sub>≤7). Patients treated with venlafaxine XR had a statistically significant superior rate of remission compared with those receiving CAs (which included mirtazapine) (59% vs 51%; <italic>p</italic>&lt;0.0001), giving a NNT of 14. Venlafaxine XR treatment also resulted in statistically significantly greater remission rates than fluoxetine, paroxetine, citalopram, or sertraline.</p>
</sec>
<sec id="section17-0269881113494937">
<title>Duloxetine versus SSRIs</title>
<sec id="section18-0269881113494937">
<title>Meta-analyses</title>
<p>Four RCT summary-level meta-analyses and two patient-level meta-analyses comparing duloxetine with SSRIs met our inclusion criteria (<xref ref-type="table" rid="table6-0269881113494937">Table 6</xref>). The largest RCT summary-level meta-analysis included 11 RCTs and only compared duloxetine with individual SSRIs (<xref ref-type="bibr" rid="bibr14-0269881113494937">Cipriani et al., 2012</xref>). The largest analysis of pooled SSRIs compared to duloxetine included nine RCTs (<xref ref-type="bibr" rid="bibr78-0269881113494937">Schueler et al., 2011</xref>). The largest patient-level meta-analysis included data from 1822 patients (<xref ref-type="bibr" rid="bibr57-0269881113494937">Mallinckrodt et al., 2007</xref>). Dosing for duloxetine in the 11 RCTs included in <xref ref-type="bibr" rid="bibr14-0269881113494937">Cipriani et al. (2012)</xref> was variable. In 6/8 comparisons with fluoxetine or paroxetine, daily duloxetine doses were force titrated to and/or fixed at 40 mg, 80 mg or 120 mg with fluoxetine and paroxetine fixed at their minimum effective doses of 20 mg. Approximately 20% of patients in the <xref ref-type="bibr" rid="bibr57-0269881113494937">Mallinckrodt et al. (2007)</xref> patient-level meta-analysis received 40 mg duloxetine as a fixed dose. SSRI dose was fixed at 20 mg/day for paroxetine and fluoxetine in all studies except one where the dose of paroxetine was 20–40 mg/day. In comparisons with escitalopram, duloxetine doses were fixed at 60 mg in all three RCTs with one study allowing flexible escitalopram doses of 10–20 mg/day, one fixed at 20 mg/day and one fixed at 10 mg/day. A placebo control was present in seven of eight RCTs vs fluoxetine and paroxetine and one of three of the RCTs comparing duloxetine with escitalopram. Baseline depression severity was mainly moderate with a mean baseline HDRS<sub>17</sub> of 17–22 in eight of the RCTs.</p>
<table-wrap id="table6-0269881113494937" position="float">
<label>Table 6.</label>
<caption>
<p>Efficacy outcomes from meta–analyses comparing duloxetine to selective serotonin reuptake inhibitors (SSRIs).</p>
</caption>
<graphic alternate-form-of="table6-0269881113494937" xlink:href="10.1177_0269881113494937-table6.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Outcome</th>
<th align="left">Publication</th>
<th align="left">RCTs or patients</th>
<th align="left">Outcome (significant outcomes in bold)</th>
<th align="left">NNT<sup><xref ref-type="table-fn" rid="table-fn12-0269881113494937">a</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="5"><bold>Duloxetine vs pooled SSRIs</bold></td>
</tr>
<tr>
<td><bold>Remission</bold></td>
<td><xref ref-type="bibr" rid="bibr57-0269881113494937">Mallinckrodt et al. (2007)</xref></td>
<td>N/A</td>
<td>Baseline HDRS<sub>17</sub>≤19 DLX 53.7%; SSRIs 48.3%</td>
<td>19</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr57-0269881113494937">Mallinckrodt et al. (2007)</xref></td>
<td>N/A</td>
<td>Baseline HDRS<sub>17</sub> 20–24 DLX 41.4%; SSRIs 41.9%</td>
<td>–200</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr57-0269881113494937">Mallinckrodt et al. (2007)</xref></td>
<td>N/A</td>
<td><bold>Baseline HDRS<sub>17</sub> ≥25 DLX 41.7% SSRIs 29.3% (<italic>p</italic>=0.034)</bold></td>
<td>9</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr88-0269881113494937">Thase et al. (2007)</xref></td>
<td>1294 patients</td>
<td>OR 1.09 (95% CI 0.86–1.38) (all patients)</td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr88-0269881113494937">Thase et al. (2007)</xref></td>
<td>1294 patients</td>
<td>DLX 40.3%; SSRIs 38.3% (<italic>p</italic>=0.49) (all patients)</td>
<td>50</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr88-0269881113494937">Thase et al. (2007)</xref></td>
<td>539 patients</td>
<td>Baseline HDRS<sub>17</sub> 15–18 DLX 46.5%; SSRIs 51.7%</td>
<td>–20</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr88-0269881113494937">Thase et al. (2007)</xref></td>
<td>755 patients</td>
<td><bold>Baseline HDRS<sub>17</sub> ≥ 19 OR 1.40 (95% CI 1.00–1.95)</bold></td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr88-0269881113494937">Thase et al. (2007)</xref></td>
<td>755 patients</td>
<td><bold>Baseline HDRS<sub>17</sub> ≥19 DLX 35.9%; SSRIs 28.6% (<italic>p</italic>=0.046)</bold></td>
<td>14</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr78-0269881113494937">Schueler et al. (2011)</xref></td>
<td>9 RCTs</td>
<td>OR 1.11 (95% CI 0.91–1.34)</td>
<td>–</td>
</tr>
<tr>
<td><bold>Response</bold></td>
<td><xref ref-type="bibr" rid="bibr78-0269881113494937">Schueler et al. (2011)</xref></td>
<td>9 RCTs</td>
<td>0.98 (95% CI 0.81–1.20)</td>
<td>–</td>
</tr>
<tr>
<td><bold>Change in HDRS</bold></td>
<td><xref ref-type="bibr" rid="bibr57-0269881113494937">Mallinckrodt et al. (2007)</xref></td>
<td>1822</td>
<td><bold>DLX −9.16; SSRIs −8.50 (<italic>p</italic>=0.032)</bold> When equalizing dose in the co–variate adjusted analysis the advantage of duloxetine was not significant (<italic>p</italic>=0.481)</td>
<td>–</td>
</tr>
<tr>
<td colspan="5"><bold>Duloxetine vs fluoxetine</bold></td>
</tr>
<tr>
<td><bold>Remission</bold></td>
<td><xref ref-type="bibr" rid="bibr14-0269881113494937">Cipriani et al. (2012a)</xref></td>
<td>2 RCTs</td>
<td>OR 0.64 (95% CI 0.35–1.17) (failure to remit)</td>
<td/>
</tr>
<tr>
<td><bold>Response</bold></td>
<td><xref ref-type="bibr" rid="bibr14-0269881113494937">Cipriani et al. (2012a)</xref></td>
<td>2 RCTs</td>
<td>OR 0.81 (0.46–1.44) (failure to respond)</td>
<td/>
</tr>
<tr>
<td><bold>SMD</bold></td>
<td><xref ref-type="bibr" rid="bibr14-0269881113494937">Cipriani et al. (2012a)</xref></td>
<td>2 RCTs</td>
<td>–0.06 (95% CI −0.41 to 0.29)</td>
<td/>
</tr>
<tr>
<td colspan="5"><bold>Duloxetine vs paroxetine</bold></td>
</tr>
<tr>
<td><bold>Response</bold></td>
<td><xref ref-type="bibr" rid="bibr30-0269881113494937">Gartlehner et al. (2011)</xref></td>
<td>5 RCTs</td>
<td>OR 0.93 (95% CI 0.72–1.22)</td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr14-0269881113494937">Cipriani et al. (2012a)</xref></td>
<td>6 RCTs</td>
<td>OR 1.12 (95% CI 0.88–1.43) (failure to response)</td>
<td/>
</tr>
<tr>
<td><bold>Remission</bold></td>
<td><xref ref-type="bibr" rid="bibr14-0269881113494937">Cipriani et al. (2012a)</xref></td>
<td>6 RCTs</td>
<td>OR 1.02 (95% CI 0.84–1.25) (failure to remit)</td>
<td>–</td>
</tr>
<tr>
<td><bold>SMD</bold></td>
<td><xref ref-type="bibr" rid="bibr14-0269881113494937">Cipriani et al. (2012a)</xref></td>
<td>6 RCTs</td>
<td>–0.05 (95% CI −0.16 –to 0.05)</td>
<td/>
</tr>
<tr>
<td colspan="5"><bold>Duloxetine vs escitalopram</bold></td>
</tr>
<tr>
<td><bold>Remission</bold></td>
<td><xref ref-type="bibr" rid="bibr17-0269881113494937">Cipriani et al. (2009b)</xref></td>
<td>3 RCTs</td>
<td>OR 0.90 (95% CI 0.62–1.29) (failure to remission ESC vs DLX)</td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr14-0269881113494937">Cipriani et al. (2012a)</xref></td>
<td>3 RCTs</td>
<td>OR 1.11 (95% CI 0.76–1.62) (failure to remission)</td>
<td/>
</tr>
<tr>
<td><bold>Response</bold></td>
<td><xref ref-type="bibr" rid="bibr17-0269881113494937">Cipriani et al. (2009b)</xref></td>
<td>3 RCTs</td>
<td>OR 0.72 (95% CI 0.43–1.20) (failure to response ESC vs DLX)</td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr14-0269881113494937">Cipriani et al. (2012a)</xref></td>
<td>3 RCTs</td>
<td>OR 1.31 (95% CI 0.87–1.97) (failure to response)</td>
<td/>
</tr>
<tr>
<td><bold>SMD in change in HDRS</bold></td>
<td><xref ref-type="bibr" rid="bibr17-0269881113494937">Cipriani et al. (2009b)</xref></td>
<td>3 RCTs</td>
<td>–0.10 (95% CI −30 to 0.09) (ESC vs DLX)</td>
<td>–</td>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr40-0269881113494937">Kennedy et al. (2009)</xref></td>
<td>1111 patients</td>
<td>–0.22 (95% CI −0.6 to 1.0) (MMRM analysis)(ESC vs DLX)</td>
<td/>
</tr>
<tr>
<td/>
<td><xref ref-type="bibr" rid="bibr14-0269881113494937">Cipriani et al. (2012a)</xref></td>
<td>3 RCTs</td>
<td>0.10 (95% CI −0.09 to 0.29)</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn11-0269881113494937">
<p>CI: confidence interval; DLX: duloxetine; ESC: escitalopram; HDRS: Hamilton Depression Rating Scale; MMRM: mixed effects model for repeated measures; N/A: not available; NNT: number needed to treat; OR: odds ratio; RCT: randomised controlled trial; SMD: standardised mean difference.</p>
</fn>
<fn id="table-fn12-0269881113494937">
<label>a</label>
<p>All presented NNTs were calculated using the reciprocal of the absolute difference in remission rates between duloxetine and SSRIs. A negative number indicates the NNT is in favour of the SSRIs.</p>
</fn>
<fn id="table-fn13-0269881113494937">
<p>Data from Cochrane reviews reported from 6–12 weeks.</p>
</fn>
<fn id="table-fn14-0269881113494937">
<p>Response defined as a reduction of ≥50% from baseline score on the HDRS, and remission as achieving an HDRS<sub>17</sub> score ≤7.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section19-0269881113494937">
<title>Duloxetine compared to pooled SSRIs</title>
<p>A remission rate in favour of duloxetine was found OR 1.1≥1 (95% CI 0.91–1.34) from the analysis of summary data from nine RCTs but this was not statistically significant (<xref ref-type="bibr" rid="bibr78-0269881113494937">Schueler et al., 2011</xref>). The two patient-level meta-analyses found significantly greater remission rates with duloxetine compared to pooled SSRIs only in patients with moderate to severe depression. <xref ref-type="bibr" rid="bibr88-0269881113494937">Thase et al. (2007)</xref> found an OR for remission of 1.40 (95% CI 1.00–1.95) in patients with a baseline HDRS<sub>17</sub> ≥ 19 in an analysis including 755 patients, and <xref ref-type="bibr" rid="bibr57-0269881113494937">Mallinckrodt et al. (2007)</xref> found remission rates of 41.7% for duloxetine and 29.3% for pooled SSRIs (<italic>p</italic>=0.034). The NNTs for remission were 14 and nine respectively.</p>
</sec>
<sec id="section20-0269881113494937">
<title>Duloxetine compared to individual SSRIs</title>
<p>Paroxetine was the most studied comparator SSRI with six RCTs included in the largest analysis (<xref ref-type="bibr" rid="bibr14-0269881113494937">Cipriani et al., 2012</xref>). An OR for failure to remit of 1.02 was found which was not statistically significantly different between treatments. Compared to fluoxetine, the OR for failure to remission from two RCTs was in favour of duloxetine (OR 0.64; 95% CI 0.35–1.17) but was not statistically significantly different. ORs for remission favoured escitalopram over duloxetine in data from three RCTs but were not statistically significantly different (<xref ref-type="bibr" rid="bibr17-0269881113494937">Cipriani et al., 2009b</xref>, 2012).</p>
</sec>
<sec id="section21-0269881113494937">
<title>Pragmatic randomised trials (<xref ref-type="table" rid="table4-0269881113494937">Table 4</xref>)</title>
<p>One pragmatic randomised trial met our inclusion criteria (<xref ref-type="bibr" rid="bibr58-0269881113494937">Martinez et al., 2012</xref>). This open-label trial compared flexible doses of duloxetine (60–120 mg/day; <italic>n</italic>=372) and flexibly dosed generic SSRIs (<italic>n</italic>=378) in adult outpatients with non-psychotic DSM-IV-Text Revision (DSM-IV-TR) MDD. Patients who had already failed treatment with a SSRI during the current depressive episode were prescribed a different SSRI in the study. After 12 weeks of treatment, remission rates (QIDS-SR score≤5) favoured duloxetine but the difference was not statistically significant. Using the secondary measure of HDRS<sub>17</sub>, patients treated with duloxetine had statistically significantly greater probabilities of response (≥50% reduction in baseline HDRS<sub>17</sub>) (73% vs 61%; <italic>p</italic>=0.001) and remission (endpoint HDRS<sub>17</sub>≤7) (53% vs 44%; <italic>p</italic>=0.034). A secondary analysis of this data has also been performed comparing duloxetine to the individual SSRIs (<xref ref-type="bibr" rid="bibr51-0269881113494937">Lenox-Smith et al., 2011</xref>). Duloxetine was found to have statistically significantly greater remission rates than citalopram (53% vs 41%; <italic>p</italic>&lt;0.05). Analysis of remission rates by baseline depression severity found some evidence for greater efficacy of duloxetine than SSRIs in more severe depression (<xref ref-type="table" rid="table4-0269881113494937">Table 4</xref>). Patients treated with duloxetine also demonstrated statistically significant greater mean changes in the HDRS<sub>17</sub> total score (−17 vs −15.3; <italic>p</italic>&lt;0.01). The NNT for remission based on the primary outcome (QIDS-SR score≤5) was 25 while that on the secondary outcome (endpoint HDRS<sub>17</sub>≤7) was 12.</p>
</sec>
<sec id="section22-0269881113494937">
<title>Milnacipran vs SSRIs</title>
<p>Two RCT summary-level meta-analyses comparing milnacipran with SSRIs met our inclusion criteria, but we did not identify any patient-level meta-analyses (<xref ref-type="table" rid="table7-0269881113494937">Table 7</xref>). Seven RCTs were included in the largest analysis (<xref ref-type="bibr" rid="bibr61-0269881113494937">Nakagawa et al., 2009</xref>). Dosing of milnacipran in included RCTs was most commonly fixed at 100 mg/day with one RCT using 150–300 mg/day and another 100–200 mg/day. Fluoxetine and paroxetine doses were fixed at 20 mg/day and fluvoxamine at 200 mg/day. No study included a placebo control, and baseline depression severity was moderate to severe (range Montgomery Asberg Depression Rating Scale (MADRS) 29–36) in the analysis reported by <xref ref-type="bibr" rid="bibr67-0269881113494937">Papakostas and Fava (2007)</xref>. No difference was found between milnacipran and pooled SSRIs in either response and remission rates or baseline to endpoint change in rating scale score. The direction of effect for response was consistently marginally in favour of milnacipran but not statistically significant. No difference was found for the only remission analysis. Data comparing milnacipran to individual SSRIs were limited with the most comparisons (three RCTs) with fluoxetine demonstrating a nonsignificant advantage for fluoxetine in response and remission. No pragmatic studies comparing milnacipran to SSRIs were identified.</p>
<table-wrap id="table7-0269881113494937" position="float">
<label>Table 7.</label>
<caption>
<p>Efficacy outcomes from randomised controlled trial (RCT) summary data meta-analyses of milnacipran compared to selective serotonin reuptake inhibitors (SSRIs).</p>
</caption>
<graphic alternate-form-of="table7-0269881113494937" xlink:href="10.1177_0269881113494937-table7.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Outcome</th>
<th align="left">Publication</th>
<th align="left">Number of RCTs in analysis</th>
<th align="left">Result (significant outcomes in bold)</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="4"><bold>Milnacipran vs pooled SSRIs</bold></td>
</tr>
<tr>
<td>Remission</td>
<td><xref ref-type="bibr" rid="bibr61-0269881113494937">Nakagawa et al. (2009)</xref></td>
<td>6</td>
<td>OR 0.98 (95% CI 0.73–1.32)</td>
</tr>
<tr>
<td>Response(MADRS) vs SSRIs</td>
<td><xref ref-type="bibr" rid="bibr67-0269881113494937">Papakostas and Fava (2007)</xref></td>
<td>6</td>
<td>RR 1.04 (95% CI 0.88–1.23)</td>
</tr>
<tr>
<td>Response rate (MADRS)</td>
<td><xref ref-type="bibr" rid="bibr67-0269881113494937">Papakostas and Fava (2007)</xref></td>
<td>6</td>
<td>MILN 58.9%; SSRIs 58.3%</td>
</tr>
<tr>
<td>Response (HDRS)</td>
<td><xref ref-type="bibr" rid="bibr67-0269881113494937">Papakostas and Fava (2007)</xref></td>
<td>5</td>
<td>RR 1.06 (95% CI 0.90–1.24)</td>
</tr>
<tr>
<td>Response rate (HDRS)</td>
<td><xref ref-type="bibr" rid="bibr67-0269881113494937">Papakostas and Fava (2007)</xref></td>
<td>5</td>
<td>MILN 59.7%; SSRIs 57.7%</td>
</tr>
<tr>
<td>Response vs SSRIs</td>
<td><xref ref-type="bibr" rid="bibr61-0269881113494937">Nakagawa et al. (2009)</xref></td>
<td>6</td>
<td>OR 1.11 (95% CI 0.76–1.64)</td>
</tr>
<tr>
<td>SMD</td>
<td><xref ref-type="bibr" rid="bibr61-0269881113494937">Nakagawa et al. (2009)</xref></td>
<td>7</td>
<td>0.04 (95% CI −0.11 to 0.19)</td>
</tr>
<tr>
<td colspan="4"><bold>Milnacipran vs fluoxetine</bold></td>
</tr>
<tr>
<td>Remission</td>
<td><xref ref-type="bibr" rid="bibr61-0269881113494937">Nakagawa et al. (2009)</xref></td>
<td>3</td>
<td>OR 0.91 (95% CI 0.56–1.46)</td>
</tr>
<tr>
<td>Response vs FLX</td>
<td><xref ref-type="bibr" rid="bibr61-0269881113494937">Nakagawa et al. (2009)</xref></td>
<td>3</td>
<td>OR 0.93 (95% CI 0.55–1.58)</td>
</tr>
<tr>
<td>SMD</td>
<td><xref ref-type="bibr" rid="bibr61-0269881113494937">Nakagawa et al. (2009)</xref></td>
<td>3</td>
<td>0.10 (95% CI −0.21 to 0.42)</td>
</tr>
<tr>
<td colspan="4"><bold>Milnacipran vs fluvoxamine</bold></td>
</tr>
<tr>
<td>SMD</td>
<td><xref ref-type="bibr" rid="bibr61-0269881113494937">Nakagawa et al. (2009)</xref></td>
<td>2</td>
<td>0.14 (95% CI −0.45 to 0.17)</td>
</tr>
<tr>
<td colspan="4"><bold>Milnacipran vs paroxetine</bold></td>
</tr>
<tr>
<td>SMD</td>
<td><xref ref-type="bibr" rid="bibr61-0269881113494937">Nakagawa et al. (2009)</xref></td>
<td>2</td>
<td>0.12 (95% CI −0.09 to 0.33)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn15-0269881113494937">
<p>CI: confidence interval; FLX: fluoxetine; HDRS: Hamilton Depression Rating Scale; MADRS: Montgomery Asberg Depression Rating Scale; MILN: milnacipran; OR: odds ratio; RR: relative risk; SMD: standard mean difference.</p>
</fn>
<fn id="table-fn16-0269881113494937">
<p>Data from Cochrane reviews reported from 6–12 weeks.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section23-0269881113494937">
<title>Desvenlafaxine vs SSRIs</title>
<p>No meta-analysis of any type or any pragmatic studies was found comparing desvenlafaxine with SSRIs.</p>
</sec>
<sec id="section24-0269881113494937">
<title>Pooled SNRIs versus pooled SSRIs</title>
<p>One meta-analysis of RCT summary data compared pooled SNRIs with pooled SSRIs using data from 15 fully published RCTs (<xref ref-type="bibr" rid="bibr54-0269881113494937">Machado and Einarson, 2010</xref>). Five RCTs compared duloxetine to SSRIs and 10 compared venlafaxine to SSRIs. Fluoxetine was the comparator SSRI in five RCTs, paroxetine in four, escitalopram in three and sertraline in three. ORs for remission and remission rates were significantly greater with the SNRIs than SSRIs (<xref ref-type="table" rid="table8-0269881113494937">Table 8</xref>).</p>
<table-wrap id="table8-0269881113494937" position="float">
<label>Table 8.</label>
<caption>
<p>Efficacy outcomes from meta-analyses comparing pooled serotonin noradrenaline reuptake inhibitors (SNRIs) and selective serotonin reuptake inhibitors (SSRIs).</p>
</caption>
<graphic alternate-form-of="table8-0269881113494937" xlink:href="10.1177_0269881113494937-table8.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Outcome</th>
<th align="left">Publication</th>
<th/>
<th align="left">Result (significant outcomes in bold)</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="4"><bold>Pooled SNRIs vs pooled SSRIs</bold></td>
</tr>
<tr>
<td><bold>Remission</bold></td>
<td><xref ref-type="bibr" rid="bibr54-0269881113494937">Machado and Einarson (2010)</xref><sup><xref ref-type="table-fn" rid="table-fn18-0269881113494937">1</xref></sup></td>
<td>15</td>
<td><bold>OR 1.27 (95% CI 1.06–1.52)</bold></td>
</tr>
<tr>
<td colspan="4"><bold>Escitalopram vs pooled SNRIs (duloxetine and venlafaxine)</bold></td>
</tr>
<tr>
<td><bold>Remission<sup><xref ref-type="table-fn" rid="table-fn18-0269881113494937">2</xref></sup></bold></td>
<td><xref ref-type="bibr" rid="bibr48-0269881113494937">Lam et al. (2010)</xref></td>
<td>132</td>
<td><bold>62% vs 41% (<italic>p</italic>=0.0083)</bold></td>
</tr>
<tr>
<td><bold>Response</bold></td>
<td><xref ref-type="bibr" rid="bibr48-0269881113494937">Lam et al. (2010)</xref></td>
<td>132</td>
<td><bold>73% vs 44% (<italic>p</italic>=0.0004)</bold></td>
</tr>
<tr>
<td><bold>SMD in MADRS scores</bold></td>
<td><xref ref-type="bibr" rid="bibr48-0269881113494937">Lam et al. (2010)</xref></td>
<td>132</td>
<td><bold>–6.4 (<italic>p</italic>&lt;0.0001)</bold></td>
</tr>
<tr>
<td>SMD in HDRS scores</td>
<td><xref ref-type="bibr" rid="bibr40-0269881113494937">Kennedy et al. (2009)</xref></td>
<td>1598</td>
<td>–0.18 (95% CI −0.5 to 0.8)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn17-0269881113494937">
<p>CI: confidence interval; HDRS: Hamilton Depression Rating Scale; MADRS: Montgomery Asberg Depression Rating Scale; OR: odds ratio; SMD: standard mean difference; RCT: randomised controlled trial; SNRI: serotonin norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor.</p>
</fn>
<fn id="table-fn18-0269881113494937">
<label>1</label>
<p>Included drugs were duloxetine (5 RCTs), venlafaxine (10 RCTs), escitalopram (3 RCTs), fluoxetine (5 RCTs), paroxetine (4 RCTs), sertraline (3 RCTs); <sup>2</sup>Remission defined as MADRS≤12.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section25-0269881113494937">
<title>Escitalopram vs pooled SNRIs</title>
<p>One meta-analysis of individual patient data (<italic>n</italic>=132) compared pooled SNRIs (duloxetine and venlafaxine) to escitalopram in patients who had failed to respond to a previous antidepressant (<xref ref-type="bibr" rid="bibr48-0269881113494937">Lam et al., 2010</xref>). Escitalopram was associated with greater remission rates than SNRIs (<xref ref-type="table" rid="table8-0269881113494937">Table 8</xref>). One meta-analysis of individual patient data compared SMD in HDRS<sub>17</sub> change using data from five RCTs including 1598 patients comparing escitalopram to pooled SNRIs (duloxetine and venlafaxine). A small advantage for escitalopram was found that was not statistically significantly different (<xref ref-type="table" rid="table8-0269881113494937">Table 8</xref>).</p>
</sec>
</sec>
<sec id="section26-0269881113494937" sec-type="discussion">
<title>Discussion</title>
<p>Our aim was to examine meta-analyses of RCTs and randomised pragmatic trials to see if there is evidence of increased efficacy of the addition of NA reuptake inhibition to 5-HT reuptake inhibition in the treatment of depression. We were able to include 22 meta-analyses of RCTs and four randomised pragmatic trials comparing efficacy between duloxetine, milnacipran and venlafaxine and SSRIs in our review. Some evidence was found that was supportive of increased efficacy of the addition of NA reuptake inhibition mostly with venlafaxine and to some extent with duloxetine, but no evidence was found for superiority of milnacipran, and we found no studies assessing the efficacy of desvenlafaxine. The NNTs were lowest and more likely to be of clinical significance in patients with moderate to severe depression.</p>
<p>The data comparing venlafaxine to pooled SSRIs was consistently supportive of increased efficacy of dual reuptake inhibition in both remission and response rates. This evidence came from several sources including meta-analyses of RCT summary data performed by several different research groups and patient-level analyses performed from the manufactures trial database and randomised pragmatic trials, thus adding strength to this finding. The data comparing venlafaxine to individual SSRIs provided mixed outcomes. Consistent evidence supports statistically significant superior efficacy compared to fluoxetine and paroxetine from meta-analyses. Although efficacy was generally in favour of venlafaxine compared to fluvoxamine and sertraline, only one of the meta-analytic findings was statistically significant. Comparisons with citalopram were equivocal and efficacy was in favour of escitalopram but not statistically significantly. One pragmatic trial did find statistical superiority of efficacy with venlafaxine compared to citalopram, fluoxetine, paroxetine and sertraline. Evidence of superior efficacy of dual reuptake inhibition from duloxetine trials was limited to data from patient level meta-analyses in patients with at least moderate to severe depression (HDRS<sub>17</sub>≥19) in comparison to pooled SSRIs and a pragmatic study also found evidence that duloxetine may be more effective than pooled SSRIs in more severe depression (QIDS SR≥21). Below we discuss the factors within the available evidence base that may have influenced the findings for each individual SNRI before we draw some general conclusions regarding the efficacy benefit of additional NA reuptake inhibition.</p>
<sec id="section27-0269881113494937">
<title>Venlafaxine</title>
<p>Several factors may have limited the ability of studies comparing venlafaxine to SSRIs to detect possible efficacy differences. Some comparisons between venlafaxine and individual SSRIs are limited by a small pool of RCTs and therefore limited statistical power. This may have been the reason why statistically significant differences were not found between venlafaxine and sertraline where ORs and rates for remission and response were mostly in favour of venlafaxine. This view is supported by the fact that there was a 7.2% remission advantage of venlafaxine over sertraline in STAR*D (<italic>p</italic>=non significant, but due to the numerous arms in this study it was underpowered to detect a statistically significant difference between SNRIs and SSRIs) and a 6.6% advantage in ARGOS (<italic>p</italic>&lt;0.042). The differences in OR for remission between venlafaxine and sertraline reported in the meta-analyses by <xref ref-type="bibr" rid="bibr21-0269881113494937">De Silva and Hanwella (2012)</xref> and <xref ref-type="bibr" rid="bibr15-0269881113494937">Cipriani et al. (2010)</xref> may be accounted for by the inclusion and exclusion of different studies in these analyses. <xref ref-type="bibr" rid="bibr21-0269881113494937">De Silva and Hanwella (2012)</xref> included a RCT with an OR for remission of 1.9 (95% CI 0.99–3.68) in favour of venlafaxine (<xref ref-type="bibr" rid="bibr59-0269881113494937">Mehtonen et al., 2000</xref>) which was not included in <xref ref-type="bibr" rid="bibr15-0269881113494937">Cipriani et al. (2010)</xref>. A different RCT (<xref ref-type="bibr" rid="bibr11-0269881113494937">Chen et al., 2001</xref>) with an OR for failure to remission of 0.92 in favour of sertraline is included in the remission analysis of <xref ref-type="bibr" rid="bibr15-0269881113494937">Cipriani et al. (2010)</xref> but not that of <xref ref-type="bibr" rid="bibr21-0269881113494937">De Silva and Hanwella (2012)</xref>. The Chen et al. study restricted venlafaxine doses to 25–100 mg/day which is below the recommended dose range of 75–375 mg/day and may account for the lack of superiority compared to sertraline which was dosed at 50–100 mg/day. The relevance of this dosing schedule to this review is that venlafaxine has been demonstrated to have a clear dose-response relationship (<xref ref-type="bibr" rid="bibr50-0269881113494937">Lecrubier, 1995</xref>; <xref ref-type="bibr" rid="bibr84-0269881113494937">Stahl et al., 2005</xref>). This may be related to the pharmacology of venlafaxine as it has been reported that at lower doses venlafaxine acts as a SSRI and does not provide clinically significant NA reuptake inhibition until it is dosed at 150 mg/day and above (<xref ref-type="bibr" rid="bibr8-0269881113494937">Blier et al., 2007</xref>; <xref ref-type="bibr" rid="bibr22-0269881113494937">Debonnel et al., 2007</xref>). The reason for this is due to its greater affinity for the 5-HT transporter than the NA transporter (<xref ref-type="bibr" rid="bibr74-0269881113494937">Richelson, 2003</xref>) meaning that higher doses need to be prescribed before clinically relevant NA reuptake inhibition takes place. The Chen et al. study may therefore have underestimated the efficacy of venlafaxine. Recently, however, a new study has created uncertainty about this conclusion. <xref ref-type="bibr" rid="bibr85-0269881113494937">Takano et al. (2013)</xref> performed an in vivo positron emission tomography study in non-human primates and found a more balanced affinity for 5-HT and NA reuptake inhibition by venlafaxine. Further studies in humans are, however, required to confirm this finding. In the response analyses, the ORs were both in favour of venlafaxine but were smaller in the Cipriani et al. analysis than the De Silva and Hanwella analysis. This may also be accounted for by different study inclusions. <xref ref-type="bibr" rid="bibr15-0269881113494937">Cipriani et al. (2010)</xref>, in addition to including the Chen et al. RCT, also include a study in ‘frail’ elderly nursing home residents (<xref ref-type="bibr" rid="bibr66-0269881113494937">Oslin et al., 2003</xref>) which strongly favours sertraline. There were significantly more early dropouts among venlafaxine users which severely limited the efficacy of venlafaxine on the intent-to-treat analysis used by Cipriani et al. Additionally the mean age of participants in this study was over 80 years and so this population is quite different from that in the majority of other included RCTs. The inclusion of these different RCTs therefore influenced the findings of the <xref ref-type="bibr" rid="bibr15-0269881113494937">Cipriani et al. (2010)</xref> meta-analysis which may therefore underestimate the efficacy of venlafaxine compared to sertraline.</p>
<p>Data from RCTs comparing venlafaxine to citalopram is very limited with only two RCTs available. The patient-level meta-analysis found a remission advantage of 3.9% in favour of venlafaxine but it was not statistically significant (<xref ref-type="bibr" rid="bibr63-0269881113494937">Nemeroff et al., 2008</xref>). One of the included RCTs used 75–150 mg/day of venlafaxine and 20–30 mg of citalopram and found a 1.4% remission advantage for citalopram (<xref ref-type="bibr" rid="bibr1-0269881113494937">Allard et al., 2004</xref>) while the other (<xref ref-type="bibr" rid="bibr52-0269881113494937">Lenox-Smith and Jiang, 2008</xref>) used dose ranges for venlafaxine of 75–300 mg/day and citalopram 20–60 mg and found a remission advantage for venlafaxine of 4.9%. The ARGOS study using flexible dosing of the full dose ranges found a remission advantage for venlafaxine over citalopram of 7.3% (<italic>p</italic>=0.024); OR: 1.34 (95% CI: 1.04–1.72); <italic>p</italic>&lt;0.05). Data using the full dose ranges of these drugs therefore is indicative of greater efficacy of venlafaxine.</p>
<p>Remission data generally favoured escitalopram over venlafaxine from two RCTs although differences were not statistically significant. There are, however, limitations to the data. One RCT restricted the dose of venlafaxine to 75–150 mg/day while allowing flexible dosing of escitalopram 10–20 mg/day (<xref ref-type="bibr" rid="bibr60-0269881113494937">Montgomery et al., 2004</xref>) and the other included a fixed dose force titrated to 225 mg/day and 20 mg of venlafaxine and escitalopram respectively after eight days (<xref ref-type="bibr" rid="bibr7-0269881113494937">Bielski et al., 2004</xref>). Thus, the first study utilised the full dose range of escitalopram but not venlafaxine and, as discussed above, this study may therefore underestimate the efficacy of venlafaxine relative to escitalopram. In the Bielski et al. study, there was a significantly higher early dropout rate in the venlafaxine group possibly due to forced titration of the starting dose to 225 mg/day. This study illustrates another potential limitation in the data as the last-observation-carried-forward (LOCF) method of accounting for missing data from early dropouts used in this study may have underestimated the efficacy of venlafaxine relative to escitalopram. Studies have demonstrated that differences in drop outs between treatments introduce significant bias in estimations of treatment efficacy using the LOCF methodology (<xref ref-type="bibr" rid="bibr49-0269881113494937">Lane, 2008</xref>; <xref ref-type="bibr" rid="bibr56-0269881113494937">Mallinckrodt et al., 2001</xref>; <xref ref-type="bibr" rid="bibr80-0269881113494937">Siddiqui et al., 2009</xref>). On this point, the LOCF method was used almost exclusively in venlafaxine RCTs, and with venlafaxine having a higher rate of early treatment discontinuation in RCTs than SSRIs (<xref ref-type="bibr" rid="bibr63-0269881113494937">Nemeroff et al., 2008</xref>; <xref ref-type="bibr" rid="bibr78-0269881113494937">Schueler et al., 2011</xref>), this method may have therefore underestimated efficacy advantages for venlafaxine across the included analyses. Additionally much of the evidence used in our review also includes studies where venlafaxine may have been primarily acting as a SSRI as 17 of 34 of the RCTs included in the <xref ref-type="bibr" rid="bibr63-0269881113494937">Nemeroff et al. (2008)</xref> analysis utilised doses of 75–150 mg. The efficacy of venlafaxine may therefore have been underestimated by some RCTs therefore impacting on the conclusions we have been able to draw about the relative efficacy of venlafaxine and SSRIs. Of note the pragmatic studies that used the full dose range of venlafaxine and SSRI comparators found efficacy advantages for venlafaxine (<xref ref-type="bibr" rid="bibr4-0269881113494937">Baldomero et al., 2005</xref>; <xref ref-type="bibr" rid="bibr75-0269881113494937">Rush et al., 2006</xref>; <xref ref-type="bibr" rid="bibr87-0269881113494937">Thase et al., 2011</xref>).</p>
<p>Regarding the clinical relevance of these findings, the NNT for remission compared to pooled SSRIs of 17 (95% CI 12–26) found in the patient-level meta-analysis (<xref ref-type="bibr" rid="bibr63-0269881113494937">Nemeroff et al., 2008</xref>), may be of clinical significance considering depression is such a common and severely disabling condition. This significance may be greatest in those with more severe depression (baseline HDRS<sub>17</sub>≥30) where the smallest NNT for remission of 11 was found (<xref ref-type="bibr" rid="bibr77-0269881113494937">Schmitt et al., 2009</xref>).</p>
</sec>
<sec id="section28-0269881113494937">
<title>Duloxetine</title>
<p>Several factors may have limited the ability of duloxetine studies to detect efficacy differences with SSRIs. The majority of duloxetine studies, however, recruited patients with relatively low baseline HDRS<sub>17</sub> of ≥15 and this may have limited the ability of meta-analyses of RCTs summary-level data to detect between treatment differences for a number of reasons. Patients with low depression severity may be more likely to spontaneously remit from their current episode regardless of drug treatment (<xref ref-type="bibr" rid="bibr53-0269881113494937">Lieberman et al., 2005</xref>). Analysis of the US Food and Drug Administration (FDA) data base of antidepressant trials has demonstrated that drug placebo differences are greater in trials that include patients with more severe depression (<xref ref-type="bibr" rid="bibr43-0269881113494937">Khan et al., 2002</xref>) and it follows that between-drug differences may also be limited in less severe depression. Furthermore, a recent analysis has also demonstrated that RCTs using the HDRS may underestimate the efficacy of antidepressants in less severe depression (<xref ref-type="bibr" rid="bibr36-0269881113494937">Isacsson and Adler, 2012</xref>). In this analysis, it was demonstrated that the sensitivity of the HDRS decreases significantly as depression severity decreases. This, it is stated, has two significant consequences. First, precision of ratings will decrease as patients improve meaning that at study endpoint ratings may have low precision, reducing the chances of finding between-treatment differences. Secondly, the sensitivity to change will decrease and therefore comparisons between patients with different baseline depression severity will not be valid for the reason that improvements in those who start on a lower severity of depression will be systematically underestimated compared with improvement starting at higher depression severities. This would therefore severely limit the ability of the RCTs to detect between-treatment differences at least in the patients with low baseline scores. All but two of the duloxetine RCTs used the HDRS as the primary outcome. This may explain why the patient level meta-analyses which were able to separately analyse the data in patients with HDRS<sub>17</sub>≥19 and ≥25 were able to detect statistically significant efficacy advantages for duloxetine compared to pooled SSRIs whereas analyses that included those at lower baseline depression levels were not. In support of this theory, the meta-analysis by <xref ref-type="bibr" rid="bibr77-0269881113494937">Schmitt et al. (2009)</xref> found the greatest OR for remission with venlafaxine compared to SSRIs in patients with the most severe baseline depression severity. It should also be noted that, in contrast to the duloxetine studies, the registration studies which compared venlafaxine to SSRIs all enrolled patients with moderate to severe depression (<xref ref-type="bibr" rid="bibr86-0269881113494937">Thase et al., 2001</xref>), possibly affording a greater likelihood of finding between-treatment differences.</p>
<p>In terms of dosing, only one of the duloxetine RCTs used optimal dosing strategies for either duloxetine or the comparator SSRIs. The majority of duloxetine studies were registration studies where the comparator SSRI was used as an assay of study sensitivity compared to placebo and the optimal dose of duloxetine was still under investigation. Six RCTs comparing duloxetine to fluoxetine and paroxetine used dosing for duloxetine either fixed at 40 mg/day or force titrated to fixed doses of 80 or 120 mg/day. Therefore, in these studies no patients used the currently recommended dose of 60 mg/day (duloxetine summary of product characteristics, available at <ext-link ext-link-type="uri" xlink:href="http://www.medicines.org.uk/emc/medicine/15694/SPC/">http://www.medicines.org.uk/emc/medicine/15694/SPC/</ext-link>). In these studies, fluoxetine and paroxetine were fixed at their minimum effective doses of 20 mg/day. Fixing the dose of antidepressants is known to reduce drug placebo differences (<xref ref-type="bibr" rid="bibr42-0269881113494937">Khan et al., 2003</xref>) and this may therefore have reduced the chances of finding between-active-treatment differences in these studies. Approximately 20% of the duloxetine patients in these studies received the 40 mg/day dose which has been demonstrated to be no more effective than placebo (<xref ref-type="bibr" rid="bibr88-0269881113494937">Thase et al., 2007</xref>). Thus, the <xref ref-type="bibr" rid="bibr78-0269881113494937">Scheuler et al. (2011)</xref> and <xref ref-type="bibr" rid="bibr14-0269881113494937">Cipriani et al. (2012a)</xref> analyses which include the patients on the 40 mg dose of duloxetine may therefore underestimate the efficacy of duloxetine. This view is supported by an analysis comparing the effect size of mean change in HDRS<sub>17</sub> of duloxetine to placebo at 40, 60, 80 and 120 mg/day which was found to increase with dose being approximately 0.30, 0.38, 0.41 and 0.44 respectively (<xref ref-type="bibr" rid="bibr57-0269881113494937">Mallinckrodt et al., 2007</xref>). <xref ref-type="bibr" rid="bibr14-0269881113494937">Cipriani et al. (2012a)</xref> performed a subgroup analysis by dose in the comparisons of duloxetine with paroxetine. The OR for failure to respond decreased in favour of duloxetine with increasing duloxetine dose. For doses less than 60 mg/day OR 1.16 (95% CI 0.66–2.05), 60 but less than 90 mg/day OR 1.11 (95% CI 0.87–1.41) and greater than 90 mg/day OR 0.89 (95% CI 0.58–1.38). It is therefore possible that the inclusion of the 40 mg/day dose influenced the findings from these RCTs and meta-analyses and a more flexible dosing strategy may have improved the efficacy of duloxetine. It must also be considered, however, that although no dose response relationship has been established for paroxetine (paroxetine summary of product characteristics, available <ext-link ext-link-type="uri" xlink:href="http://www.medicines.org.uk/emc/medicine/2057/SPC/">http://www.medicines.org.uk/emc/medicine/2057/SPC/</ext-link>), it too may have been more effective at higher doses. Currently, it is not possible to draw firm conclusions on the relative efficacy of duloxetine and paroxetine. Considering the possible influence of dose, it is also important to explore if the higher doses of duloxetine compared to the fixed minimum doses of the SSRIs were responsible for the statistically significant efficacy advantages of duloxetine in moderate to severe depression found in the patient-level meta-analyses. <xref ref-type="bibr" rid="bibr88-0269881113494937">Thase et al. (2007)</xref> found that 60, 80 and 120 mg/day were all similarly more effective than placebo suggesting that doses greater than 60 mg/day were not responsible for their finding of greater remission rates in patients with a baseline HDRS<sub>17</sub> ≥19. Similarly, as mentioned above, <xref ref-type="bibr" rid="bibr57-0269881113494937">Mallinckrodt et al. (2007)</xref> found the mean effect sizes for duloxetine compared to placebo at 60, 80 and 120 mg/day were similar being approximately 0.38, 0.41 and 0.44 respectively. The effect size advantage of pooled SSRIs over placebo at their minimum effective dose was approximately 0.29. Therefore using this meta-analytic approach, the effect size advantage of minimal effective doses of duloxetine (60 mg/day) over SSRIs was 0.09 (0.38–0.29). When Mallinckrodt et al. equalised the doses of duloxetine to 60 mg and pooled SSRIs to their minimum effective doses (fluoxetine and paroxetine 20 mg/day; escitalopram 10 mg/day) in a covariate adjusted analysis in patients with baseline HDRS<sub>17</sub> ≥25, the remission advantage for duloxetine over SSRIs was still statistically significant (<italic>p</italic>=0.033) and therefore not due to higher doses of duloxetine. The pragmatic trial comparing duloxetine to SSRIs utilised flexible and full dose ranges of duloxetine and SSRIs. For each treatment group, the percentage of patients who approached the upper limit of recommended doses by the last visit was: 58.9% duloxetine at 90–120 mg; 64.3% citalopram at 40 mg; 49.2% fluoxetine at 60–80 mg; 46.7% paroxetine at 40–50 mg; and 53.8% sertraline at 150–200 mg daily. This study therefore compares treatments with more favourable dosing strategies than the RCTs. Outcomes from this study generally favoured duloxetine in terms of remission rates in patients with higher baseline depression scores. Finally, regarding dosing, the comparisons of duloxetine with escitalopram may also be influenced by the dosing strategies employed in the RCTs. In the two RCTs favouring escitalopram, escitalopram was dosed flexibly, 10–20 mg/day (<xref ref-type="bibr" rid="bibr41-0269881113494937">Khan et al., 2007</xref>) and at its maximum licensed dose of 20 mg/day (<xref ref-type="bibr" rid="bibr90-0269881113494937">Wade et al., 2007</xref>). In contrast, the duloxetine dose was fixed at 60 mg/day in both studies, and although there is no clear evidence of a dose response relationship for duloxetine as described above, the <italic>Summary of Product Characteristics</italic> allows dosing up to a maximum of 120 mg/day and it is possible some patients may have benefitted from an increase in dose. The RCT that favoured duloxetine used fixed doses of 60 mg/day for duloxetine and the lowest effective dose for escitalopram of 10 mg/day so both antidepressants were at the lowest effective doses. Therefore, in order to draw firm conclusions on the relative efficacy of duloxetine and escitalopram, further studies using flexible doses across the licensed dose ranges should be conducted. It should also be noted that escitalopram is pharmacologically different from other SSRIs in that it is also claimed to have in addition to its 5-HT reuptake properties a pronounced effect on the serotonin transport via an affinity modulating allosteric site (<xref ref-type="bibr" rid="bibr9-0269881113494937">Chen et al., 2005</xref>) adding to its proposed mechanism of action. In a strict sense it could have been excluded from this review as this property means it differs in the interaction with the serotonergic system from the SNRIs which do not possess this action but it has been included for completeness.</p>
<p>A further factor that may have limited the ability to detect between-treatment differences is the inclusion of a placebo control in the majority of the duloxetine studies. Seven of the nine duloxetine trials included in the <xref ref-type="bibr" rid="bibr78-0269881113494937">Schueler et al. (2011)</xref> analysis and all seven contained in the largest patient-level meta-analysis (<xref ref-type="bibr" rid="bibr57-0269881113494937">Mallinckrodt et al., 2007</xref>) were placebo-controlled. The inclusion of a placebo arm in active comparator studies tends to result in a reduction in mean response and remission rates with active antidepressants (<xref ref-type="bibr" rid="bibr81-0269881113494937">Sinyor et al., 2010</xref>). This may be due to a lower expectation of benefit from participants in placebo-controlled studies as they are uncertain if they have been randomised to an active treatment or not. The placebo response rate is also around 10% higher in studies including two active antidepressants (as in these studies of duloxetine) where participants are told they have a two in three chance of receiving an active antidepressant (<xref ref-type="bibr" rid="bibr81-0269881113494937">Sinyor et al., 2010</xref>). It follows that if the placebo response is greater, this may reduce the likelihood of detecting between-active-treatment differences. Inclusion of a placebo arm also tends to result in the enrolment to a trial of a less severely ill patient group due to the prospect of receiving a placebo being a disincentive to more severely ill patients (<xref ref-type="bibr" rid="bibr53-0269881113494937">Lieberman et al., 2005</xref>), meaning that between-treatment differences are more difficult to demonstrate as described above. These two factors may have limited the ability of the duloxetine studies to detect between-treatment differences. Sensitivity analyses exploring this factor were, however, not performed in any of the meta-analyses, probably because most RCTs were placebo-controlled. With respect to the clinical significance of the reported efficacy differences between duloxetine and SSRIs, the NNTs in the more severely ill patients of 9–14 indicate that these differences may be clinically relevant.</p>
</sec>
<sec id="section29-0269881113494937">
<title>Milnacipran</title>
<p>The data comparing milnacipran to SSRIs is limited by the small number of RCTs conducted and the small numbers of patients included in each RCT. In the Cochrane review, just 569 milnacipran and 459 SSRI treated patients were included in the remission analysis (<xref ref-type="bibr" rid="bibr61-0269881113494937">Nakagawa et al., 2009</xref>). The limited number of RCTs restricted the ability to perform subgroup or sensitivity analyses so it was not possible to examine many of the variables that may have influenced findings. For example, most of the RCTs were fixed-dosed studies within the therapeutic range and it was therefore not possible to explore the effect of dose on outcome (<xref ref-type="bibr" rid="bibr61-0269881113494937">Nakagawa et al., 2009</xref>). Additionally, we were not able to identify any patient-level meta-analyses that may have been better able to explore the influence of any of these factors on outcome. The absence of any pragmatic studies means there is no additional information outside of the normal RCT setting on which to base our conclusions and, on the current evidence, milnacipran has proved to be no more effective than SSRIs.</p>
</sec>
<sec id="section30-0269881113494937">
<title>Strengths and limitations of this review</title>
<p>The main strength of our review is that we systematically searched for and examined evidence from the most recent and comprehensive meta-analyses of RCTs. We examined meta-analyses utilising different methods where available and performed by different researchers who included and excluded different RCTs and therefore we included alternative synthesis of the available data. We have examined the evidence with consideration to many of the moderating effects of trial design set out by <xref ref-type="bibr" rid="bibr53-0269881113494937">Lieberman et al. (2005)</xref> in their consensus guideline for evaluating quantitative reviews of antidepressant efficacy. We also systematically searched for, and examined, large pragmatic studies in order to check the validity of the findings in more clinically relevant populations. Our review does, however, have several limitations. First, meta-analyses and pragmatic studies have their own limitations which are also relevant to this review. In particular, meta-analyses combining data from heterogeneous studies with different dosing strategies, patient inclusion criteria and patient settings may lead to inappropriate conclusions being drawn. The meta-analyses did, however, test for significant heterogeneity between study outcomes and most used a random-effects approach to account for any significant between-study heterogeneity, but many of the meta-analyses were not able to explore the most important variables that may influence the outcomes with sensitivity analyses and subgroup analysis. Secondly we only examined acute-treatment data generally in the 6–8 weeks range and it is possible that outcomes may be different with longer-term treatment. A further limitation is the assumption that the only clinically relevant difference between the SNRIs and SSRIs we examined is the additional NA reuptake inhibition of SNRIs. This assumption is made as there is currently no evidence for other clinically relevant differences in mode of action of these antidepressants although it is possible some could emerge in the future. Finally, we have not considered tolerability of SNRIs and SSRIs in this analysis which is an important treatment consideration.</p>
</sec>
</sec>
<sec id="section31-0269881113494937" sec-type="conclusions">
<title>Overall conclusions</title>
<p>The mixed outcomes from the data mean a definitive conclusion regarding additional efficacy of the addition of NA reuptake inhibition to that of 5-HT cannot currently be drawn. The most consistent evidence of increased efficacy of dual reuptake inhibition comes from patients with more severe baseline depression as this is found with both venlafaxine and duloxetine. This suggests that duloxetine and venlafaxine would be most suitable for those patients with severe depression. The NNTs for remission of 9–14 in patients with moderate to severe depression found in these studies do suggest that any increased efficacy in these populations is clinically significant. In contrast NNTs for remission including patients with more moderate depression ranged from 14–50, suggesting a more limited clinical relevance in this patient population. These findings are, however, limited to comparisons from analyses pooling all SSRIs, and further well-designed studies comparing SNRIs to individual SSRIs, particularly escitalopram, are still required. Some evidence from two large pragmatic studies also suggests venlafaxine may be a more effective second step treatment than SSRIs in patients who fail to reach remission with a SSRI. With consideration of the current limitations of the available data, we conclude it is worthwhile to continue investigating for potentially important differences between SNRIs and SSRIs. Future studies should include patients with at least moderate to severe depression, utilise the full therapeutic dose ranges of antidepressants and examine a broader range of outcomes including remission of symptoms, function and quality of life. Additional studies where noradrenaline reuptake inhibition is added to a SSRI in patients who had not remitted during treatment with a SSRI would also be helpful.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>Andrew J Bradley and Alan J Lenox-Smith are both full time employees of Eli Lilly and Company Limited who manufacture and market duloxetine for the treatment of depression.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Andrew Bradley and Alan Lenox-Smith are full-time employees of Lilly who manufacture and market Cymbalta (duloxetine).</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Allard</surname><given-names>P</given-names></name>
<name><surname>Gram</surname><given-names>L</given-names></name>
<name><surname>Timdahl</surname><given-names>K</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: A double-blind, randomised 6-month comparative trial with citalopram</article-title>. <source>Int J Geriatr Psychiatry</source> <volume>19</volume>: <fpage>1123</fpage>–<lpage>1130</lpage>.</citation>
</ref>
<ref id="bibr2-0269881113494937">
<citation citation-type="book">
<collab>American Psychiatric Association</collab> (<year>1994</year>) <source>Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV)</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>American Psychiatric Association</publisher-name>.</citation>
</ref>
<ref id="bibr3-0269881113494937">
<citation citation-type="book">
<collab>American Psychiatric Association</collab> (<year>2000</year>) <source>Diagnostic and Statistical Manual of Mental Disorders Fourth Edition., Text Revision (DSM-IV-TR)</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>American Psychiatric Association</publisher-name>.</citation>
</ref>
<ref id="bibr4-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baldomero</surname><given-names>EB</given-names></name>
<name><surname>Ubago</surname><given-names>JG</given-names></name>
<name><surname>Cercos</surname><given-names>CL</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study</article-title>. <source>Depress Anxiety</source> <volume>22</volume>: <fpage>68</fpage>–<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr5-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ballesteros</surname><given-names>J</given-names></name>
<name><surname>Callado</surname><given-names>LF</given-names></name>
<name><surname>Gutierrez</surname><given-names>M</given-names></name>
</person-group> (<year>2007</year>) <article-title>An independent meta-analysis using summary data for clinical response, remission, and discontinuation for any reason from the 6 pivotal phase III randomized clinical trials of duloxetine in major depressive disorder</article-title>. <source>J Clin Psychopharmacol</source> <volume>27</volume>: <fpage>219</fpage>–<lpage>221</lpage>.</citation>
</ref>
<ref id="bibr6-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bauer</surname><given-names>M</given-names></name>
<name><surname>Tharmanathan</surname><given-names>P</given-names></name>
<name><surname>Volz</surname><given-names>HP</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: A meta-analysis</article-title>. <source>Eur Arch Psychiatry Clin Neurosci</source> <volume>259</volume>: <fpage>172</fpage>–<lpage>185</lpage>.</citation>
</ref>
<ref id="bibr7-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bielski</surname><given-names>RJ</given-names></name>
<name><surname>Ventura</surname><given-names>D</given-names></name>
<name><surname>Chang</surname><given-names>CC</given-names></name>
</person-group> (<year>2004</year>) <article-title>A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder</article-title>. <source>J Clin Psychiatry</source> <volume>65</volume>: <fpage>1190</fpage>–<lpage>1196</lpage>.</citation>
</ref>
<ref id="bibr8-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Blier</surname><given-names>P</given-names></name>
<name><surname>Saint-Andre</surname><given-names>E</given-names></name>
<name><surname>Hebert</surname><given-names>C</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers</article-title>. <source>Int J Neuropsychopharmacol</source> <volume>10</volume>: <fpage>41</fpage>–<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr9-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>F</given-names></name>
<name><surname>Larsen</surname><given-names>MB</given-names></name>
<name><surname>Sanchez</surname><given-names>C</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors</article-title>. <source>Eur Neuropsychopharmacol</source> <volume>15</volume>: <fpage>193</fpage>–<lpage>198</lpage>.</citation>
</ref>
<ref id="bibr10-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>X</given-names></name>
<name><surname>Huang</surname><given-names>X</given-names></name>
<name><surname>Hu</surname><given-names>Y</given-names></name>
</person-group> (<year>2012</year>) <article-title>Efficacy and safety of Duloxetine versus paroxetine for adults’ depression: A meta-analysis</article-title>. <source>Chinese Journal of Evidence-Based Medicine</source> <volume>12</volume>: <fpage>320</fpage>–<lpage>325</lpage>.</citation>
</ref>
<ref id="bibr11-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>ZM</given-names></name>
<name><surname>Zhang</surname><given-names>JH</given-names></name>
<name><surname>Li</surname><given-names>ZW</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Venlafaxine versus imipramine,sertraline in treating depression</article-title>. . <source>Chinese Journal of New Drugs and Clinical Remedies</source> <volume>20</volume>: <fpage>109</fpage>–<lpage>111</lpage>.</citation>
</ref>
<ref id="bibr12-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cipriani</surname><given-names>A</given-names></name>
<name><surname>Brambilla</surname><given-names>P</given-names></name>
<name><surname>Furukawa</surname><given-names>T</given-names></name>
<etal/>
</person-group>. (<year>2005</year>) <article-title>Fluoxetine versus other types of pharmacotherapy for depression</article-title>. <source>Cochrane Database Syst Rev</source>: <fpage>CD004185</fpage>.</citation>
</ref>
<ref id="bibr13-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cipriani</surname><given-names>A</given-names></name>
<name><surname>Furukawa</surname><given-names>TA</given-names></name>
<name><surname>Salanti</surname><given-names>G</given-names></name><etal/>
</person-group>. (<year>2009a</year>) <article-title>Comparative efficacy and acceptability of 12 newgeneration antidepressants: A multiple-treatments meta-analysis</article-title>. <source>Lancet</source> <volume>373</volume>: <fpage>746</fpage>–<lpage>758</lpage>.</citation>
</ref>
<ref id="bibr14-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cipriani</surname><given-names>A</given-names></name>
<name><surname>Koesters</surname><given-names>M</given-names></name>
<name><surname>Furukawa</surname><given-names>TA</given-names></name><etal/>
</person-group>. (<year>2012a</year>) <article-title>Duloxetine versus other anti-depressive agents for depression</article-title>. <source>Cochrane Database Syst Rev</source> <volume>10</volume>: <fpage>CD006533</fpage>.</citation>
</ref>
<ref id="bibr15-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cipriani</surname><given-names>A</given-names></name>
<name><surname>La Ferla</surname><given-names>T</given-names></name>
<name><surname>Furukawa</surname><given-names>TA</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Sertraline versus other antidepressive agents for depression</article-title>. <source>Cochrane Database Syst Rev</source>: <fpage>D006117</fpage>.</citation>
</ref>
<ref id="bibr16-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cipriani</surname><given-names>A</given-names></name>
<name><surname>Purgato</surname><given-names>M</given-names></name>
<name><surname>Furukawa</surname><given-names>TA</given-names></name>
<etal/>
</person-group>. (<year>2012b</year>) <article-title>Citalopram versus other anti-depressive agents for depression</article-title>. <source>Cochrane Database Syst Rev 7</source>: <fpage>CD006534</fpage>.</citation>
</ref>
<ref id="bibr17-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cipriani</surname><given-names>A</given-names></name>
<name><surname>Santilli</surname><given-names>C</given-names></name>
<name><surname>Furukawa</surname><given-names>TA</given-names></name><etal/>
</person-group>. (<year>2009b</year>) <article-title>Escitalopram versus other antidepressive agents for depression</article-title>. <source>Cochrane Database Syst Rev</source>: <volume>2</volume>; <fpage>CD006532</fpage>.</citation>
</ref>
<ref id="bibr18-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cook</surname><given-names>RJ</given-names></name>
<name><surname>Sackett</surname><given-names>DL</given-names></name>
</person-group> (<year>1995</year>) <article-title>The number needed to treat: A clinically useful measure of treatment effect</article-title>. <source>Brit Med J</source> <volume>310</volume>: <fpage>452</fpage>–<lpage>454</lpage>.</citation>
</ref>
<ref id="bibr19-0269881113494937">
<citation citation-type="journal">
<collab>Danish University Antidepressant Group (DUAG)</collab> (<year>1986</year>) <article-title>Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicenter study</article-title>. <source>Psychopharmacology (Berl)</source> <volume>90</volume>: <fpage>131</fpage>–<lpage>138</lpage>.</citation>
</ref>
<ref id="bibr20-0269881113494937">
<citation citation-type="journal">
<collab>Danish University Antidepressant Group (DUAG)</collab> (<year>1990</year>) <article-title>Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study</article-title>. <source>J Affect Disord</source> <volume>18</volume>: <fpage>289</fpage>–<lpage>299</lpage>.</citation>
</ref>
<ref id="bibr21-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Silva</surname><given-names>VA</given-names></name>
<name><surname>Hanwella</surname><given-names>R</given-names></name>
</person-group> (<year>2012</year>) <article-title>Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: A meta-analysis of published studies</article-title>. <source>Int Clin Psychopharmacol</source> <volume>27</volume>: <fpage>8</fpage>–<lpage>16</lpage>.</citation>
</ref>
<ref id="bibr22-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Debonnel</surname><given-names>G</given-names></name>
<name><surname>Saint-Andre</surname><given-names>E</given-names></name>
<name><surname>Hebert</surname><given-names>C</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Differential physiological effects of a low dose and high doses of venlafaxine in major depression</article-title>. <source>Int J Neuropsychopharmacol</source> <volume>10</volume>: <fpage>51</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr23-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Deecher</surname><given-names>DC</given-names></name>
<name><surname>Beyer</surname><given-names>CE</given-names></name>
<name><surname>Johnston</surname><given-names>G</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor</article-title>. <source>J Pharmacol Exp Ther</source> <volume>318</volume>: <fpage>657</fpage>–<lpage>665</lpage>.</citation>
</ref>
<ref id="bibr24-0269881113494937">
<citation citation-type="web">
<source>Duloxetine Summary of Product Characterisitics</source>, <publisher-name>Eli Lilly and Company Limited</publisher-name>. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.medicines.org.uk/emc/medicine/15694/SPC/">http://www.medicines.org.uk/emc/medicine/15694/SPC/</ext-link> (<access-date>accessed 15 June 2013</access-date>).</citation>
</ref>
<ref id="bibr25-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eckert</surname><given-names>L</given-names></name>
<name><surname>Lancon</surname><given-names>C</given-names></name>
</person-group> (<year>2006</year>) <article-title>Duloxetine compared with fluoxetine and venlafaxine: Use of meta-regression analysis for indirect comparisons</article-title>. <source>BMC Psychiatry</source> <volume>6</volume>: <fpage>30</fpage>.</citation>
</ref>
<ref id="bibr26-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Einarson</surname><given-names>TR</given-names></name>
<name><surname>Addis</surname><given-names>A</given-names></name>
<name><surname>Mittmann</surname><given-names>N</given-names></name><etal/>
</person-group>. (<year>1998</year>) <article-title>Meta-analysis of venlafaxine, SSRIs and TCAs in the treatment of major depressive disorder</article-title>. <source>Can J Clin Pharmacol</source> <volume>5</volume>: <fpage>205</fpage>–<lpage>216</lpage>.</citation>
</ref>
<ref id="bibr27-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Einarson</surname><given-names>TR</given-names></name>
<name><surname>Arikian</surname><given-names>SR</given-names></name>
<name><surname>Casciano</surname><given-names>J</given-names></name><etal/>
</person-group>. (<year>1999</year>) <article-title>Comparison of extended-release venlafaxine, serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: A meta-analysis of randomized controlled trials</article-title>. <source>Clin Ther</source> <volume>21</volume>: <fpage>296</fpage>–<lpage>308</lpage>.</citation>
</ref>
<ref id="bibr28-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Entsuah</surname><given-names>AR</given-names></name>
<name><surname>Huang</surname><given-names>H</given-names></name>
<name><surname>Thase</surname><given-names>ME</given-names></name>
</person-group> (<year>2001</year>) <article-title>Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo</article-title>. <source>J Clin Psychiatry</source> <volume>62</volume>: <fpage>869</fpage>–<lpage>877</lpage>.</citation>
</ref>
<ref id="bibr29-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gartlehner</surname><given-names>G</given-names></name>
<name><surname>Gaynes</surname><given-names>BN</given-names></name>
<name><surname>Hansen</surname><given-names>RA</given-names></name><etal/>
</person-group>. (<year>2008a</year>) <article-title>Comparative benefits and harms of second-generation antidepressants: Background paper for the American College of Physicians</article-title>. <source>Ann Intern Med</source> <volume>149</volume>: <fpage>734</fpage>–<lpage>750</lpage>.</citation>
</ref>
<ref id="bibr30-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gartlehner</surname><given-names>G</given-names></name>
<name><surname>Hansen</surname><given-names>RA</given-names></name>
<name><surname>Morgan</surname><given-names>LC</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis</article-title>. <source>Ann Intern Med</source> <volume>155</volume>: <fpage>772</fpage>–<lpage>785</lpage>.</citation>
</ref>
<ref id="bibr31-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gartlehner</surname><given-names>G</given-names></name>
<name><surname>Thieda</surname><given-names>P</given-names></name>
<name><surname>Hansen</surname><given-names>RA</given-names></name>
<etal/>
</person-group>. (<year>2008b</year>) <article-title>Comparative risk for harms of second-generation antidepressants : A systematic review and meta-analysis</article-title>. <source>Drug Saf</source> <volume>31</volume>: <fpage>851</fpage>–<lpage>865</lpage>.</citation>
</ref>
<ref id="bibr32-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gartlehner</surname><given-names>G</given-names></name>
<name><surname>Thaler</surname><given-names>K</given-names></name>
<name><surname>Hansen</surname><given-names>RA</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysis</article-title>. <source>Drug Saf</source> <volume>32</volume>: <fpage>1159</fpage>–<lpage>1173</lpage>.</citation>
</ref>
<ref id="bibr33-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Girardi</surname><given-names>P</given-names></name>
<name><surname>Pompili</surname><given-names>M</given-names></name>
<name><surname>Innamorati</surname><given-names>M</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Duloxetine in acute major depression: Review of comparisons to placebo and standard antidepressants using dissimilar methods</article-title>. <source>Hum Psychopharmacol</source> <volume>24</volume>: <fpage>177</fpage>–<lpage>190</lpage>.</citation>
</ref>
<ref id="bibr34-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hansen</surname><given-names>RA</given-names></name>
<name><surname>Gartlehner</surname><given-names>G</given-names></name>
<name><surname>Lohr</surname><given-names>KN</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder</article-title>. <source>Ann Intern Med</source> <volume>143</volume>: <fpage>415</fpage>–<lpage>426</lpage>.</citation>
</ref>
<ref id="bibr35-0269881113494937">
<citation citation-type="web">
<person-group person-group-type="editor">
<name><surname>Higgins</surname><given-names>JPT</given-names></name>
<name><surname>Green</surname><given-names>S</given-names></name>
</person-group> (eds) (<year>2011</year>) <source>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</source>. <publisher-name>The Cochrane Collaboration</publisher-name>. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.cochrane-handbook.org">www.cochrane-handbook.org</ext-link>.</citation>
</ref>
<ref id="bibr36-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Isacsson</surname><given-names>G</given-names></name>
<name><surname>Adler</surname><given-names>M</given-names></name>
</person-group> (<year>2012</year>) <article-title>Randomized clinical trials underestimate the efficacy of antidepressants in less severe depression</article-title>. <source>Acta Psychiatr Scand</source> <volume>125</volume>: <fpage>453</fpage>–<lpage>459</lpage>.</citation>
</ref>
<ref id="bibr37-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kasper</surname><given-names>S</given-names></name>
<name><surname>Spadone</surname><given-names>C</given-names></name>
<name><surname>Verpillat</surname><given-names>P</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Onset of action of escitalopram compared with other antidepressants: Results of a pooled analysis</article-title>. <source>Int Clin Psychopharmacol</source> <volume>21</volume>: <fpage>105</fpage>–<lpage>110</lpage>.</citation>
</ref>
<ref id="bibr38-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Katzman</surname><given-names>MA</given-names></name>
<name><surname>Tricco</surname><given-names>AC</given-names></name>
<name><surname>McIntosh</surname><given-names>D</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis</article-title>. <source>J Clin Psychiatry</source> <volume>68</volume>: <fpage>1845</fpage>–<lpage>1859</lpage>.</citation>
</ref>
<ref id="bibr39-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kennedy</surname><given-names>SH</given-names></name>
<name><surname>Andersen</surname><given-names>HF</given-names></name>
<name><surname>Lam</surname><given-names>RW</given-names></name>
</person-group> (<year>2006</year>) <article-title>Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis</article-title>. <source>J Psychiatry Neurosci</source> <volume>31</volume>: <fpage>122</fpage>–<lpage>131</lpage>.</citation>
</ref>
<ref id="bibr40-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kennedy</surname><given-names>SH</given-names></name>
<name><surname>Andersen</surname><given-names>HF</given-names></name>
<name><surname>Thase</surname><given-names>ME</given-names></name>
</person-group> (<year>2009</year>) <article-title>Escitalopram in the treatment of major depressive disorder: A meta-analysis</article-title>. <source>Curr Med Res Opin</source> <volume>25</volume>: <fpage>161</fpage>–<lpage>175</lpage>.</citation>
</ref>
<ref id="bibr41-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Khan</surname><given-names>A</given-names></name>
<name><surname>Bose</surname><given-names>A</given-names></name>
<name><surname>Alexopoulos</surname><given-names>GS</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder</article-title>. <source>Clin Drug Investig</source> <volume>27</volume>: <fpage>481</fpage>–<lpage>492</lpage>.</citation>
</ref>
<ref id="bibr42-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Khan</surname><given-names>A</given-names></name>
<name><surname>Khan</surname><given-names>SR</given-names></name>
<name><surname>Walens</surname><given-names>G</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: An analysis of the Food and Drug Administration summary basis of approval reports</article-title>. <source>Neuropsychopharmacology</source> <volume>28</volume>: <fpage>552</fpage>–<lpage>557</lpage>.</citation>
</ref>
<ref id="bibr43-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Khan</surname><given-names>A</given-names></name>
<name><surname>Leventhal</surname><given-names>RM</given-names></name>
<name><surname>Khan</surname><given-names>SR</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>Severity of depression and response to antidepressants and placebo: An analysis of the Food and Drug Administration database</article-title>. <source>J Clin Psychopharmacol</source> <volume>22</volume>: <fpage>40</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr44-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kobak</surname><given-names>KA</given-names></name>
<name><surname>Taylor</surname><given-names>LH</given-names></name>
<name><surname>Dottl</surname><given-names>SL</given-names></name><etal/>
</person-group>. (<year>1997</year>) <article-title>A computer-administered telephone interview to identify mental disorders</article-title>. <source>JAMA</source> <volume>278</volume>: <fpage>905</fpage>–<lpage>910</lpage>.</citation>
</ref>
<ref id="bibr45-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koesters</surname><given-names>M</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Ma</surname><given-names>YC</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>What can we learn from Chinese randomized controlled trials? A systematic review and meta-analysis of Chinese venlafaxine studies</article-title>. <source>J Clin Psychopharmacol</source> <volume>31</volume>: <fpage>194</fpage>–<lpage>200</lpage>.</citation>
</ref>
<ref id="bibr46-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kornstein</surname><given-names>SG</given-names></name>
<name><surname>Li</surname><given-names>D</given-names></name>
<name><surname>Mao</surname><given-names>Y</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: Integrative analysis of four double-blind, randomized clinical trials</article-title>. <source>CNS Spectr</source> <volume>14</volume>: <fpage>326</fpage>–<lpage>333</lpage>.</citation>
</ref>
<ref id="bibr47-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lam</surname><given-names>RW</given-names></name>
<name><surname>Andersen</surname><given-names>HF</given-names></name>
<name><surname>Wade</surname><given-names>AG</given-names></name>
</person-group> (<year>2008</year>) <article-title>Escitalopram and duloxetine in the treatment of major depressive disorder: A pooled analysis of two trials</article-title>. <source>Int Clin Psychopharmacol</source> <volume>23</volume>: <fpage>181</fpage>–<lpage>187</lpage>.</citation>
</ref>
<ref id="bibr48-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lam</surname><given-names>RW</given-names></name>
<name><surname>Lonn</surname><given-names>SL</given-names></name>
<name><surname>Despiegel</surname><given-names>N</given-names></name>
</person-group> (<year>2010</year>) <article-title>Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: A pooled analysis</article-title>. <source>Int Clin Psychopharmacol</source> <volume>25</volume>: <fpage>199</fpage>–<lpage>203</lpage>.</citation>
</ref>
<ref id="bibr49-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lane</surname><given-names>P</given-names></name>
</person-group> (<year>2008</year>) <article-title>Handling drop-out in longitudinal clinical trials: A comparison of the LOCF and MMRM approaches</article-title>. <source>Pharm Stat</source> <volume>7</volume>: <fpage>93</fpage>–<lpage>106</lpage>.</citation>
</ref>
<ref id="bibr50-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lecrubier</surname><given-names>Y</given-names></name>
</person-group> (<year>1995</year>) <article-title>Clinical utility of venlafaxine in comparison with other antidepressants</article-title>. <source>Int Clin Psychopharmacol</source> <volume>10</volume>: <fpage>S29</fpage>–<lpage>S35</lpage>.</citation>
</ref>
<ref id="bibr51-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lenox-Smith</surname><given-names>A</given-names></name>
<name><surname>Macdonald</surname><given-names>M</given-names></name>
<name><surname>Bradley</surname><given-names>A</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Duloxetine vs individual generic selective serotonin reuptake inhibitors (SSRIs) in the treatment of a severe depressive episode</article-title>. <source>J Psychopharmacol</source> <volume>25</volume>: <fpage>A19</fpage>.</citation>
</ref>
<ref id="bibr52-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lenox-Smith</surname><given-names>AJ</given-names></name>
<name><surname>Jiang</surname><given-names>Q</given-names></name>
</person-group> (<year>2008</year>) <article-title>Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor</article-title>. <source>Int Clin Psychopharmacol</source> <volume>23</volume>: <fpage>113</fpage>–<lpage>119</lpage>.</citation>
</ref>
<ref id="bibr53-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lieberman</surname><given-names>JA</given-names></name>
<name><surname>Greenhouse</surname><given-names>J</given-names></name>
<name><surname>Hamer</surname><given-names>RM</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Comparing the effects of antidepressants: Consensus guidelines for evaluating quantitative reviews of antidepressant efficacy</article-title>. <source>Neuropsychopharmacology</source> <volume>30</volume>: <fpage>445</fpage>–<lpage>460</lpage>.</citation>
</ref>
<ref id="bibr54-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Machado</surname><given-names>M</given-names></name>
<name><surname>Einarson</surname><given-names>TR</given-names></name>
</person-group> (<year>2010</year>) <article-title>Comparison of SSRIs and SNRIs in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials</article-title>. <source>J Clin Pharm Ther</source> <volume>35</volume>: <fpage>177</fpage>–<lpage>188</lpage>.</citation>
</ref>
<ref id="bibr55-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Machado</surname><given-names>M</given-names></name>
<name><surname>Iskedjian</surname><given-names>M</given-names></name>
<name><surname>Ruiz</surname><given-names>I</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Remission, dropouts, and adverse drug reaction rates in major depressive disorder: A meta-analysis of head-to-head trials</article-title>. <source>Curr Med Res Opin</source> <volume>22</volume>: <fpage>1825</fpage>–<lpage>1837</lpage>.</citation>
</ref>
<ref id="bibr56-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mallinckrodt</surname><given-names>CH</given-names></name>
<name><surname>Clark</surname><given-names>WS</given-names></name>
<name><surname>David</surname><given-names>SR</given-names></name>
</person-group> (<year>2001</year>) <article-title>Accounting for dropout bias using mixed-effects models</article-title>. <source>J Biopharm Stat</source> <volume>11</volume>: <fpage>9</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr57-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mallinckrodt</surname><given-names>CH</given-names></name>
<name><surname>Prakash</surname><given-names>A</given-names></name>
<name><surname>Houston</surname><given-names>JP</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Differential antidepressant symptom efficacy: Placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram)</article-title>. <source>Neuropsychobiology</source> <volume>56</volume>: <fpage>73</fpage>–<lpage>85</lpage>.</citation>
</ref>
<ref id="bibr58-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Martinez</surname><given-names>JM</given-names></name>
<name><surname>Katon</surname><given-names>W</given-names></name>
<name><surname>Greist</surname><given-names>JH</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode</article-title>. <source>Int Clin Psychopharmacol</source> <volume>27</volume>: <fpage>17</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr59-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mehtonen</surname><given-names>OP</given-names></name>
<name><surname>Sogaard</surname><given-names>J</given-names></name>
<name><surname>Roponen</surname><given-names>P</given-names></name><etal/>
</person-group>. (<year>2000</year>) <article-title>Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group</article-title>. <source>J Clin Psychiatry</source> <volume>61</volume>: <fpage>95</fpage>–<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr60-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Montgomery</surname><given-names>SA</given-names></name>
<name><surname>Huusom</surname><given-names>AK</given-names></name>
<name><surname>Bothmer</surname><given-names>J</given-names></name>
</person-group> (<year>2004</year>) <article-title>A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder</article-title>. <source>Neuropsychobiology</source> <volume>50</volume>: <fpage>57</fpage>–<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr61-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nakagawa</surname><given-names>A</given-names></name>
<name><surname>Watanabe</surname><given-names>N</given-names></name>
<name><surname>Omori</surname><given-names>IM</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Milnacipran versus other antidepressive agents for depression</article-title>. <source>Cochrane Database Syst Rev</source>: <fpage>CD006529</fpage>.</citation>
</ref>
<ref id="bibr62-0269881113494937">
<citation citation-type="book">
<collab>National Institute for Health and Clinical Excellence</collab> (<year>2010</year>) <source>The Treatment and Management of Depression in Adults. National Clinical Guideline 90</source>, <publisher-loc>London</publisher-loc>: <publisher-name>National Institue for Health and Clinical Excellence</publisher-name>.</citation>
</ref>
<ref id="bibr63-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nemeroff</surname><given-names>CB</given-names></name>
<name><surname>Entsuah</surname><given-names>R</given-names></name>
<name><surname>Benattia</surname><given-names>I</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs</article-title>. <source>Biol Psychiatry</source> <volume>63</volume>: <fpage>424</fpage>–<lpage>434</lpage>.</citation>
</ref>
<ref id="bibr64-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Omori</surname><given-names>IM</given-names></name>
<name><surname>Watanabe</surname><given-names>N</given-names></name>
<name><surname>Nakagawa</surname><given-names>A</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: Meta-analysis</article-title>. <source>J Psychopharmacol</source> <volume>23</volume>: <fpage>539</fpage>–<lpage>550</lpage>.</citation>
</ref>
<ref id="bibr65-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Omori</surname><given-names>IM</given-names></name>
<name><surname>Watanabe</surname><given-names>N</given-names></name>
<name><surname>Nakagawa</surname><given-names>A</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Fluvoxamine versus other anti-depressive agents for depression</article-title>. <source>Cochrane Database Syst Rev</source>: <fpage>CD006114</fpage>.</citation>
</ref>
<ref id="bibr66-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oslin</surname><given-names>DW</given-names></name>
<name><surname>Ten Have</surname><given-names>TR</given-names></name>
<name><surname>Streim</surname><given-names>JE</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Probing the safety of medications in the frail elderly: Evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents</article-title>. <source>J Clin Psychiatry</source> <volume>64</volume>: <fpage>875</fpage>–<lpage>882</lpage>.</citation>
</ref>
<ref id="bibr67-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Papakostas</surname><given-names>GI</given-names></name>
<name><surname>Fava</surname><given-names>M</given-names></name>
</person-group> (<year>2007</year>) <article-title>A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder</article-title>. <source>Eur Neuropsychopharmacol</source> <volume>17</volume>: <fpage>32</fpage>–<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr68-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Papakostas</surname><given-names>GI</given-names></name>
<name><surname>Fava</surname><given-names>M</given-names></name>
<name><surname>Thase</surname><given-names>ME</given-names></name>
</person-group> (<year>2008</year>) <article-title>Treatment of SSRI-resistant depression: A meta-analysis comparing within- versus across-class switches</article-title>. <source>Biol Psychiatry</source> <volume>63</volume>: <fpage>699</fpage>–<lpage>704</lpage>.</citation>
</ref>
<ref id="bibr69-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Papakostas</surname><given-names>GI</given-names></name>
<name><surname>Thase</surname><given-names>ME</given-names></name>
<name><surname>Fava</surname><given-names>M</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents</article-title>. <source>Biol Psychiatry</source> <volume>62</volume>: <fpage>1217</fpage>–<lpage>1227</lpage>.</citation>
</ref>
<ref id="bibr70-0269881113494937">
<citation citation-type="web">
<source>Paroxetine Summary of Product Characterisitcs GlaxoSmithKline</source>. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.medicines.org.uk/emc/medicine/2057/SPC/">http://www.medicines.org.uk/emc/medicine/2057/SPC/</ext-link> (<access-date>accessed 15 June 2013</access-date>).</citation>
</ref>
<ref id="bibr71-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Puech</surname><given-names>A</given-names></name>
<name><surname>Montgomery</surname><given-names>SA</given-names></name>
<name><surname>Prost</surname><given-names>JF</given-names></name><etal/>
</person-group>. (<year>1997</year>) <article-title>Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: An overview of its antidepressant activity and clinical tolerability</article-title>. <source>Int Clin Psychopharmacol</source> <volume>12</volume>:<fpage>99</fpage>–<lpage>108</lpage>.</citation>
</ref>
<ref id="bibr72-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Puozzo</surname><given-names>C</given-names></name>
<name><surname>Panconi</surname><given-names>E</given-names></name>
<name><surname>Deprez</surname><given-names>D</given-names></name>
</person-group> (<year>2002</year>) <article-title>Pharmacology and pharmacokinetics of milnacipran</article-title>. <source>Int Clin Psychopharmacol</source> <volume>17</volume>: <fpage>S25</fpage>–<lpage>S35</lpage>.</citation>
</ref>
<ref id="bibr73-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ramsberg</surname><given-names>J</given-names></name>
<name><surname>Asseburg</surname><given-names>C</given-names></name>
<name><surname>Henriksson</surname><given-names>M</given-names></name>
</person-group> (<year>2012</year>) <article-title>Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model</article-title>. <source>PLoS One</source> <volume>7</volume>: <fpage>e42003</fpage>.</citation>
</ref>
<ref id="bibr74-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Richelson</surname><given-names>E</given-names></name>
</person-group> (<year>2003</year>) <article-title>Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance</article-title>. <source>J Clin Psychiatry</source> <volume>64</volume>: <fpage>S5</fpage>–<lpage>S12</lpage>.</citation>
</ref>
<ref id="bibr75-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rush</surname><given-names>AJ</given-names></name>
<name><surname>Trivedi</surname><given-names>MH</given-names></name>
<name><surname>Wisniewski</surname><given-names>SR</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression</article-title>. <source>N Engl J Med</source> <volume>354</volume>: <fpage>1231</fpage>–<lpage>1242</lpage>.</citation>
</ref>
<ref id="bibr76-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schacht</surname><given-names>A</given-names></name>
<name><surname>Dyachkova</surname><given-names>Y</given-names></name>
<name><surname>Walton</surname><given-names>RJ</given-names></name>
</person-group> (<year>2013</year>) <article-title>Critical evaluation of mixed treatment comparison meta-analyses using examples assessing antidepressants and opioid detoxification treatments</article-title>. <source>Int J Methods Psychiatr Res</source> <volume>22</volume>: <fpage>166</fpage>–<lpage>174</lpage>.</citation>
</ref>
<ref id="bibr77-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schmitt</surname><given-names>AB</given-names></name>
<name><surname>Bauer</surname><given-names>M</given-names></name>
<name><surname>Volz</surname><given-names>HP</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity</article-title>. <source>Eur Arch Psychiatry Clin Neurosci</source> <volume>259</volume>: <fpage>329</fpage>–<lpage>339</lpage>.</citation>
</ref>
<ref id="bibr78-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schueler</surname><given-names>YB</given-names></name>
<name><surname>Koesters</surname><given-names>M</given-names></name>
<name><surname>Wieseler</surname><given-names>B</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>A systematic review of duloxetine and venlafaxine in major depression, including unpublished data</article-title>. <source>Acta Psychiatr Scand</source> <volume>123</volume>: <fpage>247</fpage>–<lpage>265</lpage>.</citation>
</ref>
<ref id="bibr79-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shelton</surname><given-names>C</given-names></name>
<name><surname>Entsuah</surname><given-names>R</given-names></name>
<name><surname>Padmanabhan</surname><given-names>SK</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo</article-title>. <source>Int Clin Psychopharmacol</source> <volume>20</volume>: <fpage>233</fpage>–<lpage>238</lpage>.</citation>
</ref>
<ref id="bibr80-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Siddiqui</surname><given-names>O</given-names></name>
<name><surname>Hung</surname><given-names>HM</given-names></name>
<name><surname>O’Neill</surname><given-names>R</given-names></name>
</person-group> (<year>2009</year>) <article-title>MMRM vs LOCF: A comprehensive comparison based on simulation study and 25 NDA datasets</article-title>. <source>J Biopharm Stat</source> <volume>19</volume>: <fpage>227</fpage>–<lpage>246</lpage>.</citation>
</ref>
<ref id="bibr81-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sinyor</surname><given-names>M</given-names></name>
<name><surname>Levitt</surname><given-names>AJ</given-names></name>
<name><surname>Cheung</surname><given-names>AH</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses</article-title>. <source>J Clin Psychiatry</source> <volume>71</volume>: <fpage>270</fpage>–<lpage>279</lpage>.</citation>
</ref>
<ref id="bibr82-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>D</given-names></name>
<name><surname>Dempster</surname><given-names>C</given-names></name>
<name><surname>Glanville</surname><given-names>J</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis</article-title>. <source>Br J Psychiatry</source> <volume>180</volume>: <fpage>396</fpage>–<lpage>404</lpage>.</citation>
</ref>
<ref id="bibr83-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stahl</surname><given-names>SM</given-names></name>
<name><surname>Entsuah</surname><given-names>R</given-names></name>
<name><surname>Rudolph</surname><given-names>RL</given-names></name>
</person-group> (<year>2002</year>) <article-title>Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression</article-title>. <source>Biol Psychiatry</source> <volume>52</volume>: <fpage>1166</fpage>–<lpage>1174</lpage>.</citation>
</ref>
<ref id="bibr84-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stahl</surname><given-names>SM</given-names></name>
<name><surname>Grady</surname><given-names>MM</given-names></name>
<name><surname>Moret</surname><given-names>C</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>SNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants</article-title>. <source>CNS Spectr</source> <volume>10</volume>: <fpage>732</fpage>–<lpage>747</lpage>.</citation>
</ref>
<ref id="bibr85-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Takano</surname><given-names>A</given-names></name>
<name><surname>Halldin</surname><given-names>C</given-names></name>
<name><surname>Farde</surname><given-names>L</given-names></name>
</person-group> (<year>2013</year>) <article-title>SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: A PET study</article-title>. <source>Psychopharmacology (Berl)</source> <volume>226</volume>: <fpage>147</fpage>–<lpage>153</lpage>.</citation>
</ref>
<ref id="bibr86-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thase</surname><given-names>ME</given-names></name>
<name><surname>Entsuah</surname><given-names>AR</given-names></name>
<name><surname>Rudolph</surname><given-names>RL</given-names></name>
</person-group> (<year>2001</year>) <article-title>Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors</article-title>. <source>Br J Psychiatry</source> <volume>178</volume>: <fpage>234</fpage>–<lpage>241</lpage>.</citation>
</ref>
<ref id="bibr87-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thase</surname><given-names>ME</given-names></name>
<name><surname>Ninan</surname><given-names>PT</given-names></name>
<name><surname>Musgnung</surname><given-names>JJ</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: A randomized, open-label study</article-title>. <source>Prim Care Companion CNS Disord</source> <volume>13</volume>(<issue>1</issue>):<fpage>e1</fpage>-<lpage>e9</lpage>.</citation>
</ref>
<ref id="bibr88-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thase</surname><given-names>ME</given-names></name>
<name><surname>Pritchett</surname><given-names>YL</given-names></name>
<name><surname>Ossanna</surname><given-names>MJ</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Efficacy of duloxetine and selective serotonin reuptake inhibitors: Comparisons as assessed by remission rates in patients with major depressive disorder</article-title>. <source>J Clin Psychopharmacol</source> <volume>27</volume>: <fpage>672</fpage>–<lpage>676</lpage>.</citation>
</ref>
<ref id="bibr89-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Trivedi</surname><given-names>MH</given-names></name>
<name><surname>Rush</surname><given-names>AJ</given-names></name>
<name><surname>Wisniewski</surname><given-names>SR</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice</article-title>. <source>Am J Psychiatry</source> <volume>163</volume>: <fpage>28</fpage>–<lpage>40</lpage>.</citation>
</ref>
<ref id="bibr90-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wade</surname><given-names>A</given-names></name>
<name><surname>Gembert</surname><given-names>K</given-names></name>
<name><surname>Florea</surname><given-names>I</given-names></name>
</person-group> (<year>2007</year>) <article-title>A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder</article-title>. <source>Curr Med Res Opin</source> <volume>23</volume>: <fpage>1605</fpage>–<lpage>1614</lpage>.</citation>
</ref>
<ref id="bibr91-0269881113494937">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weinmann</surname><given-names>S</given-names></name>
<name><surname>Becker</surname><given-names>T</given-names></name>
<name><surname>Koesters</surname><given-names>M</given-names></name>
</person-group> (<year>2008</year>) <article-title>Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis</article-title>. <source>Psychopharmacology (Berl)</source> <volume>196</volume>: <fpage>511</fpage>-<lpage>520</lpage>; discussion 521–512.</citation>
</ref>
</ref-list>
</back>
</article>